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Metastatic disease is the major cause of death in all solid tumor 
cancers. Current therapeutic strategies fail to target metastasis as the 
genes and mechanisms that regulate this process remain poorly 
understood. Metastatic colonization is the final step of the metastatic 
cascade whereby cancer cells form a tumor at a distant site. This final step 
is the culmination of clonal evolution of cancer populations that results in 
a highly aggressive population with enhanced metastatic capacity and 
often presents clinically as numerous inoperable tumor nodules that lead 
to mortality. Characterization of the mechanisms that govern metastatic 
colonization at cellular and molecular levels is necessary for the 
prevention and treatment of metastatic disease in patients. 
The first half of this thesis presents work towards understanding 
mechanisms that mediate colorectal cancer colonization of the liver in 
order to guide novel therapeutic strategies. An in vivo large-scale RNA-
interference screen was performed to identify genes required for liver 
colonization. Liver and red blood cell pyruvate kinase (PKLR) was 
identified as a driver of liver metastasis in experimental models. In 
patients, PKLR was found to be expressed at higher levels in liver 
metastases relative to primary colorectal cancer tumors and also over-
expressed in the primary tumors of patients with metastatic disease. PKLR 
was found to promote cell survival in the tumor core and enhance 
survival during conditions of concurrent high cell density and low oxygen 
availability. Molecular studies revealed that PKL negatively regulates 
pyruvate kinase M2 (PKM2) enzymatic activity.  By inhibiting cellular 
pyruvate kinase activity, PKLR allows for the diversion of metabolites 
towards glutathione generation—allowing for the maintenance of 
glutathione levels. Adequate glutathione levels appears critical for 
metastatic colonization as GCLC, the catalytic subunit of glutamate-
cysteine ligase and the rate-limiting enzyme for glutathione synthesis, was 
found to be similarly required for effective metastasis, associated in its 
expression with human liver metastatic progression, and could be 
therapeutically targeted to reduce metastatic colonization. These findings 
highlight the impact of metabolic regulation on cancer cell adaptation 
within the metastatic niche.  The robust effects on liver metastatic 
colonization observed upon modulating this metabolic pathway suggest 
clinical potential for therapeutic targeting of PKLR or cellular glutathione 
synthesis in colorectal cancer. 
The second half of this thesis presents work towards an 
understanding of diversity generation in clonal populations as it benefits 
cancer evolution and metastatic colonization. Clonal human breast cancer 
subpopulations were isolated to allow for the identification of 
subpopulations that exhibit population-level phenotypic diversity. These 
high variability clonal subpopulations were found to be more proficient at 
metastatic colonization—consistent with a positive role for diversification 
capacity in cancer progression. Through single-cell RNA-sequencing, cell-
to-cell transcript expression variability was identified as a defining feature 
of these subpopulations, extending to protein-level variability. 
Furthermore, spliceosomal machinery was identified as a gene set with 
high expression variability, suggesting a means by which variation could 
be transmitted to a global level. Engineered variable expression of the 
spliceosomal gene SNRNP40 promoted metastatic fitness, and this 
metastatic capacity was attributable to cells with low SNRNP40 
expression. Clinically, low SNRNP40 expression is associated with 
metastatic relapse. These findings reveal that transcriptomic variability 
generation may serve as a mechanism by which cancer subpopulations 
achieve diversification of gene expression states, which allows for 
enhanced fitness under changing environmental pressures encountered 
during metastatic progression.   
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CHAPTER 1: Introduction 
2 
Metastasis as a major cause of cancer death 
Cancer is the second most common cause of death in the United 
States, accounting for an estimated 589,430 deaths in 2015 (Siegel et al., 
2015). It is estimated that 90% of these deaths is a result of metastasis, 
when cancer cells leave the site of the primary tumor and develop a tumor 
in a distant organ (Mehlen and Puisieux, 2006; Weigelt et al., 2005). 
Despite the significant clinical impact, current therapies fail to affect 
metastatic outcomes, which is highlighted by the drastically low 5-year 
survival rates of metastatic breast and colorectal cancer, two of the most 
prevalent and deadly cancers in the US (Figure 1.1)(Siegel et al., 2015). 
There currently does not exist any therapy with broad metastasis-
suppressive activity as the mechanisms that regulate metastasis remain 
poorly characterized (Chiang and Massague, 2008).  
Figure 1.1: 5-year survival for breast and colorectal cancer 
Survival rates as calculated by Siegal et al., 2015 for breast (a) and 
colorectal (b) cancers. Local stage is defined as no spread to lymph nodes 
or nearby structures. Regional stage is defined as spread to nearby tissues 
or lymph nodes. Distant stage is defined as spread to distant lymph nodes 
or organs. 
 3 
The metastatic cascade and organ tropism 
 Metastasis is a complex, multi-step process whereby cancer cell 
populations survive and expand through a series of different selective 
pressures before a tumor can form in a distant organ (Illustration 1.1). 
During early stages of metastasis, cancer must first locally invade through 
the basement membrane of the tissue wall, allowing for access to local 
lymphatic and hematogenous circulation (Gupta and Massague, 2006; 
Valastyan and Weinberg, 2011). Cancer populations must survive in 
circulation until arrival at a distant organ, where successful extravasation, 
adaptation to microenvironmental pressures, and cancer population 
growth must occur to allow for continued cancer progression (Talmadge 
and Fidler, 2010). Metastatic colonization is the final step of this process, 
which is defined as the capacity of cancer cells that have arrested at a 
distant organ to develop into macroscopic metastatic tumor nodules.   
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Illustration 1.1: The metastatic cascade 
Cancer populations that develop in the primary site must invade through 
the basement membrane, intravasate into circulation, survive in transit 
until arresting at a distant organ. Populations must then successfully 
extravasate into the distant organ where colonization must occur before a 
macroscopic metastasis is formed. 
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Much of the difficulty in broadly impacting metastasis in the clinic 
can be attributed to the heterogeneity of metastasis. While primary tumors 
from cancers of different types harbor similar oncogenic and tumor-
suppressive mutations that enables deregulation of pathways essential to 
tumorigenesis (Hanahan and Weinberg, 2000), metastatic cancer varies in 
its presentation clinically and in its phenotypic capabilities depending on 
the cancer type. Clinicians have long been aware that cancer types differ 
in their propensity to colonize distant organs—metastatic breast cancer 
most commonly occurs in the lung, liver, bone and brain, whereas 
metastatic colorectal cancer most commonly occurs in the liver (Fidler, 
2003). This inherent propensity was originally attributed to anatomy as it 
was proposed by Virchow in 1858 that cancer cells dislodged from a 
primary tumor follow circulation to form emboli in the vasculature of 
distant organs (Virchow, 1989). This theory was further advanced by 
Ewing in 1928 who proposed that circulatory architecture and mechanical 
forces dictated organ specificity (Ewing, 1928). The countering theory of 
metastasis was developed by Paget in 1889, who noted from autopsy 
records that in addition to the lungs, metastatic breast cancer 
preferentially colonized bones, liver and ovaries—organs that do not 
immediately follow the breast in the circulatory system (Paget, 1989).  This 
preferential metastatic colonization led Paget to generate the “seed-and-
soil” hypothesis in which he posited that cancer cells disseminate to many 
organs, but that macroscopic metastases develop only at the sites 
permissive to cancer cell survival and growth. Studies by Fidler nearly a 
century later revealed that while cancer cells arrive and can arrest in 
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nearly all organs, metastatic colonization only occurs in select organs, 
confirming Paget’s hypothesis and indicating that biological factors at the 
metastatic niche can dictate organ specificity (Hart and Fidler, 1980). Fider 
and colleagues also demonstrated that subpopulations in a primary tumor 
contribute to the metastatic population, indicating that cancer cells possess 
inherent biological features that enable metastatic potential (Fidler and 
Kripke, 1977). Together, it is now understood that molecular drivers from 
both the cancer cells as well as the metastatic niche contribute to the 
development of macroscopic metastases. 
 Organ tropism has been validated at the molecular level where 
functional studies have revealed distinct molecular drivers in breast 
cancer populations enable proclivities to colonize the bone, brain, lung, 
and liver (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005; Tabaries et 
al., 2011). Importantly, metastatic cancer cells require distinct phenotypic 
abilities to colonize different organs. Breast and melanoma cancer cells 
that colonize the lung depend heavily on the ability to migrate through 
endothelium, invade through extracellular matrix, and recruit endothelial 
cells for continued tumor growth (Pencheva et al., 2012; Png et al., 2012; 
Tavazoie et al., 2008). Colorectal cancer appears more dependent on 
adequate cancer cell energetic supply to survive in the hypoxic liver 
microenvironment during initial colonization of the liver (Loo et al., 2015). 
Molecular and cellular characterization of these driver genes and 
pathways in various cancer types and organs have allowed for the 
potential development of novel strategies to therapeutically target 
metastasis (Loo et al., 2015; Pencheva et al., 2014; Pencheva et al., 2012). 
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The heterogeneity between cancer types illustrates how focused 
characterization of cancer type-specific mechanisms that govern 
metastatic colonization can be translated into clinical therapies.  
Clonal evolution during the metastatic cascade 
The understanding of the metastatic cascade as a step-wise 
progression of a population with increasing aggressiveness is based on the 
model of clonal evolution of cancer populations first proposed by Nowell 
in 1976 (Nowell, 1976). Based on Darwinian natural selection, this model 
proposes that cancer populations progress via mutational events that 
provide a fitness advantage through rounds of selective pressures 
(Illustration 1.2). This model was delineated in patients most notably by 
Vogelstein who observed an association between specific driver mutations 
with the aggressiveness of early stage of colorectal cancer (Vogelstein et 
al., 1988). More recently, whole-genome sequencing has revealed that 
within individual tumors, subclonal expansion of cancer populations 
during cancer progression can be attributed to the effect of specific driver 
mutations (Ding et al., 2012; Gerlinger et al., 2012; Juric et al., 2015), 
consistent with Nowell’s model. 
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Illustration 1.2: Clonal evolution of cancer populations 
Cancer progresses by generating mutational diversity, which impacts 
phenotypic differences in a population, depicted by varying cell color. 
Variation in phenotypes leads to increased fitness in a subset of the 
population, enabling survival when faced with a selective pressure, 
depicted by the gray bar, and subsequent clonal expansion. This process is 
repeated through multiple rounds until a highly aggressive cancer 
population is generated. 
The original theory behind the evolution of cancer populations can 
be extended to current areas of interest in the cancer biology field. First, 
the inherent variation in the population originally defined as genetic in 
nature now includes epigenetic mutational events. Many cancers are can 
be driven by epigenetic processes, where variation in histone 
modifications can predict tumor recurrence (Seligson et al., 2005). 
Furthermore, the clonal evolution theory can be applied to the metastatic 
cascade as each step poses a significant impediment to cell survival and 
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division. Importantly, the final step of metastatic colonization is a highly 
selective step with an estimation that less than 0.01% of cells that arrive at 
a distant organ are able to form metastases (Fidler, 1970). Cancer 
populations at this step would greatly benefit from an increase in 
phenotypic variation, leading to higher success at this evolutionary 
bottleneck (Merlo et al., 2006). Characterization of mechanisms that 
generate phenotypic diversity in a cancer population has the ability to 
impact understanding and the prevention of metastasis formation 
broadly. 
Benefit of diversity to cancer evolution 
Generation of phenotypic diversity is beneficial if the phenotype 
serves to increase survival and reproduction. Acquisition of the hallmarks 
of cancer, such as self-sufficient growth, limitless replication potential and 
evasion of apoptosis, translate into an increase in population fitness 
(Hanahan and Weinberg, 2000). The initial acquisition of these features 
and subsequent clonal expansion is best understood in the context of 
genetic alterations. During DNA replication, spontaneous mutations can 
occur in normal cells at a rate of 10-6 to 10-7 mutations per cell division 
(Araten et al., 2005), which may lead to a rare yet significant cancer-
initiating event. However, with an estimated 3-12 mutations required to 
initiate cancer (Renan, 1993), it was argued that this background mutation 
rate is insufficient to cause cancer (Loeb, 1991). The discovery of 
mutations in DNA repair genes in hereditary nonpolyposis colorectal 
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cancer revealed a mutator phenotype that can enhance cancer progression 
by increasing the rate at which mutations occur, which increases the 
probability that oncogenes and tumor suppressors become genetically 
altered (Fishel et al., 1993; Leach et al., 1993; Rampino et al., 1997; Renault 
et al., 1996). These cancer-promoting mutations in individual cells lead to 
their clonal expansion into a significant proportion of a given tumor; high-
throughput sequencing of different regions within individual tumors have 
revealed spatial genetic heterogeneity and evolutionary history of a cancer 
as it progressed (de Bruin et al., 2014; Gerlinger et al., 2012; Navin et al., 
2011; Park et al., 2010). After iterative rounds of clonal selection and 
expansion, a large number of genetic variants can exist in a population. It 
is estimated that there may be approximately 1,000-3,000 mutations per 
cancer cell and on the order of 1012 mutations in a tumor (Bielas et al., 
2006), although the majority are in non-coding regions or have neutral 
effect on fitness. This number of mutations observed corresponds to a 200-
fold higher mutational rate in cancers as compared to normal cells (Klein, 
2006). This capacity to generate genetic diversity in cancer population 
allows for cancer progression at a rate much higher than chance alone.  
Nevertheless, any heritable change in subclonal populations that 
provides a fitness advantage will enable clonal expansion and cancer 
progression. Most notably, epigenetic mutations and modifications are 
understood to occur more readily as compared to genetic mutations and 
thus, significantly contribute to cancer progression (Baylin and Herman, 
2000; Feinberg et al., 2006). Heterogeneity of histone modification patterns 
has been shown to be of predictive utility for prostate cancer recurrence 
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(Seligson et al., 2005). One mechanism by which epigenetic mutations 
contribute to population diversity is through inactivating 
hypermethylation of DNA-damage response and repair genes, leading to 
genetic instability (Horie-Inoue and Inoue, 2006; Weisenberger et al., 
2006). However, additional mechanisms by which epigenetic alterations 
contribute to phenotypic diversity remain poorly characterized and 
warrant further investigation. 
 From an ecological perspective, metastasis is perceived as the 
colonization of a new habitat, which is dependent on the invasive ability 
of the cancer cells as well as features of the new ecosystem (Merlo et al., 
2006). Ecological studies have indicated the benefit of increased species 
complexity for invaders of a new habitat (Shea and Chesson, 2002), while 
studies in bacteria similarly indicated that population fitness is dependent 
on population diversity (Imhof and Schlotterer, 2006). Importantly, 
metastasis poses numerous selective pressures that the generation of 
phenotypic diversity would provide a significant fitness advantage. 
Furthermore, analysis of metastases from breast, colorectal and pancreatic 
cancers have revealed limited genetic alterations as compared to primary 
tumors (Ding et al., 2010; Jones et al., 2008; Yachida et al., 2010), 
suggesting that genetic instability may be insufficient for the acquisition of 
metastatic capacity. Thus, the acquisition of metastatic capacity may in 
part be driven by non-genetic mechanisms. 
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Colonization at end organ is the clinically relevant event 
 While metastasis involves numerous sequential steps, end organ 
colonization is a critical event as it is the point at which metastatic disease 
can first be clinically diagnosed. Biologically, as compared to all the 
phenotypic selections required throughout metastatic cascade, end organ 
colonization has experimentally been demonstrated to be one of the most 
rate-limiting selective pressures. Xenograft inoculation of human cancer 
cells into immune-deficient mice was the first in vivo experimental method 
that enabled study of end organ colonization (Fidler, 1986; Rygaard and 
Povlsen, 1969). Initial studies by Fidler observed that upon intravenous 
inoculation of melanoma cells, while less than 0.1% of cells could survive 
circulation, less than 0.01% of these surviving cells could produce 
experimental metastases (Fidler, 1970). More recently, intermediate steps 
of the metastatic cascade that include survival in circulation, arrest at a 
distant organ, and extravasation were observed to occur efficiently—80% 
of intravenously inoculated cells successfully extravasated. However, the 
ability to form macroscopic metastases was calculated to be less than 
0.02% (Luzzi et al., 1998).  
This selectivity is observed analogously in patients. Among ovarian 
cancer patients who received peritoneovenous shunts to treat peritoneal 
ascites, effectively releasing tens of millions of cancer cells into circulation, 
many never developed metastases (Tarin et al., 1984). Furthermore, 
among thousands of breast cancer patients who exhibited 
micrometastases in their bone marrow at diagnosis, only 50% developed 
overt metastases within 10 years (Braun et al., 2005). The development of 
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macroscopic metastases is ultimately the cause of mortality. Given the 
selectivity, clinical intervention to target metastatic colonization would 
reduce the likelihood of successful therapeutic resistance and escape. The 
characterization of genes and mechanisms that regulate this process 
would provide significant benefit towards improving patient survival.  
 
Objectives 
 The goal of this thesis is to characterize mechanisms involved in 
metastatic colonization. Two approaches were performed. The first 
portion of this thesis was to characterize key signaling molecules that 
drive colorectal cancer metastatic liver colonization in order to develop 
novel therapeutic strategies. Using an in vivo large-scale RNAi screen, 
liver and red blood cell pyruvate kinase (PKLR) was identified as a driver 
of liver metastatic colonization. In patients, PKLR expression was 
increased in liver metastases as well as in primary tumors of patients with 
metastatic disease. PKLR promoted cell survival in the tumor core during 
conditions of high cell-density and oxygen deprivation through increasing 
glutathione levels. PKLR was found to negatively regulate the glycolytic 
activity of PKM2, a master metabolic regulator involved in controlling 
glycolytic flux as well cellular glutathione levels. Glutathione appeared to 
be critical for metastasis as GCLC, the rate-limiting enzyme for 
glutathione synthesis, was similarly required for liver colonization and 
could be therapeutically inhibited to reduce metastatic colonization. These 
findings highlighted the impact of metabolic re-programming within the 
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niche as metastases progress and suggested clinical potential for targeting 
this pathway in colorectal cancer.  
 The second portion of this thesis was to characterize mechanisms 
by which breast cancer cells may generate diversity as an enhancement for 
clonal evolution and metastatic fitness. These mechanisms could 
potentially be relevant in many cancer types as clonal evolution pertains 
to all contexts of metastasis. Clonal human breast cancer subpopulations 
were isolated that displayed substantial population-level phenotypic 
diversity. These high variability clonal subpopulations were more 
proficient at metastatic colonization—consistent with a positive role for 
diversification capacity in cancer progression. Through single-cell RNA-
sequencing, cell-to-cell transcript expression variation was identified as a 
defining feature of these subpopulations, extending to protein-level 
variation. Furthermore, spliceosomal machinery was identified as a gene 
set with high expression variability, suggesting a means by which 
variation could be transmitted to a global level. Engineered variable 
expression of spliceosomal gene SNRNP40 promoted metastatic fitness, 
attributable to cells with low SNRNP40 expression. Clinically, low 
SNRNP40 expression was found to be associated with metastatic relapse. 
The experimental model established here could be applied to various 
cancers to better understand non-genetic contributions to heterogeneity 
and to study the impact of such deregulation amongst cancer populations 
and their progeny.  
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CHAPTER 2: PKLR Promotes Colorectal Cancer Liver Colonization by 
Increasing Glutathione Levels 
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2.1 Introduction 
Clinical need for therapies against metastatic colorectal cancer 
One cancer type that would greatly benefit from improved 
therapeutic options is colorectal cancer, the third most common cancer 
and the third leading cause of cancer death in America (Siegel et al., 2015). 
In 2015, 132,700 new cases are expected to be diagnosed, while 49,700 
individuals are expected to die from colorectal cancer. In the past few 
decades, incidence and death rates have decreased largely due to 
improved prevention and detection through screening. The adoption of 
colonoscopy as a highly sensitive screening method has enabled both the 
detection of adenomatous polyps, which can be removed to prevent 
cancer development (Corley et al., 2014; Zauber et al., 2012), as well as the 
detection of early-stage cancer, which allows for potentially curative 
surgery and greatly improved outcomes (Nishihara et al., 2013). When 
colorectal cancer is localized to the intestine, the five-year relative survival 
rate is nearly 90%. 
Despite the effectiveness of colorectal cancer screening, only 59% of 
the US population aged fifty years and older participates in screening 
measures. Because early-stage disease is often asymptomatic, those who 
do not participate in these screening measures can develop undetected 
disease that slowly progresses to advanced stages over the course of ten to 
twenty years (Winawer and Zauber, 2002). As a result, distant disease is 
found in 25% of all initially diagnosed patients and develops in 40-50% of 
newly diagnosed patients (Van Cutsem et al., 2009). This translates to a 
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five-year survival of 13% for those with metastatic disease (Davies and 
Goldberg, 2011; Ferlay et al., 2014). 
 While localized disease can be cured with surgery in the majority of 
cases, metastatic disease is associated with the worst prognosis with the 
liver being the most common site of distant disease. Curative surgical 
resection of liver metastases may be achieved only in a minority of cases. 
However, relapse after resection occurs in 75% of these patients 
(Nordlinger et al., 1996), and the five-year survival rate for those who 
relapse remains low at only 36% (Rees et al., 2008). Importantly, for the 
majority of cases, surgery is not possible, and chemotherapy remains the 
only therapeutic option to extend life.  
 Current chemotherapy regimens are based on 5-fluorouracil (5-FU), 
a pyrimidine analog that was introduced and adopted for clinical use in 
the 1950s (Heidelberger et al., 1957). 5-fluorouracil was found to 
incorporate into DNA during replication and inhibit RNA synthesis, 
leading to decreased cell growth and proliferation. This growth-inhibitory 
effect was first observed in solid tumors implanted in mice, and rapidly 
was translated to clinical responses in patients with a variety of cancer 
types (Curreri et al., 1958). Leucovorin (LV), a vitamin that inhibits 
thymidylate synthase, was added to enhance 5-fluorouracil efficacy (Poon 
et al., 1989). While 5-FU/LV showed significant efficacy in prolonging life, 
this combination exhibited no major impact on overall survival (1992). 
 Alkylating agents such as oxaliplatin and irinotecan were included 
more recently, forming the current cytotoxic chemotherapy combination 
regimens, FOLFOX (5-FU/LV/oxaliplatin) (de Gramont et al., 2000) and 
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FOLFIRI (5-FU/LV/irinotecan) (Saltz et al., 2000). Despite significant 
effects on progression-free survival time, modest effects on overall 
survival time, and nuanced changes to timing and delivery strategies, 
only 10% of patients live beyond five years since metastases ultimately 
lose responsiveness to these therapies (Davies and Goldberg, 2011). 
Molecularly targeting therapies such as the VEGF inhibitor bevacizumab 
and EGFR inhibitor cetuximab have marginally improved survival by 
delaying progression, though patients eventually do succumb to the 
disease (Davies and Goldberg, 2011). At this point, the current 
chemotherapy regimen mainly serves a palliative role to extend survival 
and improve quality of life (Glimelius et al., 1994). For a therapy to have 
curative potential, strategies specific against metastasis-promoting 
phenotypes must be developed to limit progression at rate-limiting steps 
where resistance will be less readily acquired. With metastatic disease in 
the liver being the life-limiting aspect for late-stage colon cancer patients, 
characterization of metastatic colonization and progression would provide 
significant advances towards the development of more effective therapies. 
 
Mechanisms of colorectal cancer progression 
 Colorectal cancer arises through a progression of mutational and 
transformative events on epithelial tissue that allows for increasing 
aggressiveness. The initiating event is often the acquisition of genomic 
instability. Genomic instability can arise by DNA hypermethylation in 
fifteen percent of sporadic cases, while germ-line mutations in DNA 
 19 
repair machinery predisposes patients to a high likelihood of colorectal 
cancer (Markowitz and Bertagnolli, 2009). The most common mode of 
genomic instability is through chromosomal instability. This early genetic 
deregulation allows for hyperplastic growth and proliferation, 
characteristic of adenomatous polyps. Uncontrolled growth and 
continued genetic instability leads to inactivating mutations in critical 
tumor-suppressor genes such as APC, p53, and SMAD4 and activating 
mutations in oncogenes such as K-RAS, BRAF, and PIK3CA (Markowitz 
and Bertagnolli, 2009)(Illustration 3.1). These genes regulate cellular 
processes that when deregulated, help define fundamental aspects of 
cancer regardless of cancer type, which include self-sufficiency in growth 
signaling, resistance to anti-growth signals, evasion of apoptosis, and 
limitless replicative potential (Hanahan and Weinberg, 2000). Continued 
evolution of cancer populations led to even more aggressive phenotypes, 
eventually progressing into invasive and disseminated disease. The model 
of progressive acquisition of cancer-promoting mutations is supported by 
the observed genetic profile of primary tumors of different grades (Fearon 
and Vogelstein, 1990; Vogelstein et al., 1988). Progression into metastasis 
is understood to be an evolutionary process whereby clonal selection of 
cancer cells with the highest fitness at a phenotypic level allows for 
population advancement (Nowell, 1976; Talmadge and Fidler, 2010). 
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Illustration 2.1: Genetic progression of colorectal cancer 
Progression of colorectal cancer is shown with known genetic alterations 
that contribute to cancer development. MSI = microsatellite instability,  
CIN = chromosomal instability 
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Metastatic colonization of the liver 
To clinically impact colorectal cancer, the process of liver 
colonization must be better characterized (Talmadge and Fidler, 2010; 
Valastyan and Weinberg, 2011). Metastatic colonization, the formation of 
macroscopic metastases, has been observed to be a significant rate-limiting 
step during metastatic liver growth (Luzzi et al., 1998). This selective 
pressure may be in part attributable to the liver microenvironment, which 
is marked by hypoxic regions, a unique circulatory architecture, and 
significant metabolic activity (Jungermann and Kietzmann, 1996). The 
genes and pathways most suitable for therapeutic inhibition would be 
those whose expression is necessary for colonization events. Furthermore, 
it remains unclear whether cancer cells utilize different mechanisms for 
early or late colonization events (Sullivan and Christofk, 2015). Early 
metastatic colonization can be achieved through utilization of liver-
derived energetic molecules to enhance survival upon arrival in the 
hypoxic, nutrient-poor liver microenvironment (Loo et al., 2015). 
However, therapeutics that target early colonization are only useful for 
prevention of metastatic nodule formation. Late colonization events, 
which contribute to the continued progression of macro-metastases, 
represent a stage with significant clinical need given that patients who 
develop liver metastases exhibit a poor prognosis and that approximately 
twenty percent of patients initially present with distant metastatic disease 
(Siegel et al., 2014). Nevertheless, both early and late metastatic 
colonization remain poorly characterized and must be systematically 
 22 
approached for the development of biologically relevant therapeutic 
strategies. 
 
Functional genomics in cancer 
 The identification of the key regulators of metastatic colonization 
can benefit from a systematic, functional approach. Classical genetic 
screening approaches utilized chemical and transposon-based 
mutagenesis, allowing for the unbiased identification of genes responsible 
for the biological process of interest (Boutros and Ahringer, 2008). 
However, the process of identification and characterization of the genes of 
interest is time-consuming and laborious. Additionally, complex 
phenotypes and the large size of the mammalian genome render classical 
screening approaches infeasible (Boutros and Ahringer, 2008). The 
discovery and application of RNAi for screening purposes has enabled 
large-scale screening in mammalian systems (Elbashir et al., 2001) (Root et 
al., 2006). RNAi screens in cancer were first applied to identify essential 
genes for cancer cell proliferation and survival (Luo et al., 2008; Schlabach 
et al., 2008; Silva et al., 2008; Whitehurst et al., 2007). More recent 
applications have brought this screening technique to cancer progression 
in vivo, enabling the characterization of pathological and developmental 
processes under more physiological conditions (Beronja et al., 2013; Zuber 
et al., 2011). Utilization of large-scale loss-of-function screens has enabled 
the identification and characterization of novel regulators of disease 
processes.   
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2.2 Identification of kinases that promote liver colonization 
 
Large-scale in vivo shRNA screen for promoters of liver colonization  
 To molecularly study colorectal cancer colonization in the liver, a 
large-scale in vivo shRNA screen was performed to identify key regulatory 
genes (Figure 2.1). Three human colon cancer cell lines, LS174T, SW620 
and WiDr, representing the mutational spectrum commonly seen in 
patients (Kras wild-type/mutant, Braf wild-type/mutant, MSS/MSI), 
were transduced with shRNA-encoding lentiviral particles. Ten subpools 
were used in total that included 54,591 total hairpins targeting 14,095 
human genes. Cells were transduced at a low titer to ensure only a single 
shRNA would be incorporated into a cell. These transduced cell 
populations were then divided into three fractions. The first fraction was 
saved as a reference population to account for shRNA inserts initially 
present. A second fraction was inoculated into immuno-deficient mice by 
direct liver injection for the selection of cells capable of colonizing the 
liver. The third fraction was grown in culture to select for cells capable of 
basal growth and survival. Once tumors had developed in the liver, these 
tumors were harvested, and all three fractions were processed to isolate 
genomic DNA and amplify the incorporated shRNA inserts for high-
throughput sequencing. Sequencing allowed for quantification of shRNA 
inserts and calculation of relative depletion of shRNAs from tumors and 
cultured cells. Loss of shRNA representation from the tumors would 
suggest that depletion of the targeted genes suppressed the ability of 
colon cancer cells to colonize the liver. 
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Figure 2.1: Large-scale shRNA screen for promoters of liver metastasis  
Schematic of pooled shRNA library dropout screen. Colon cancer cell lines 
were transduced with an shRNA library and subject to direct liver 
injections (top), growth in culture (bottom), and reference sample (T0, 
middle). Samples were processed to allow for sequencing of shRNA 
inserts to allow for identification of genes that promote liver colonization 
as well as genes that promote population growth. 
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 Analysis of shRNA profiling revealed significant depletion of 
shRNAs across all cell lines in both tumors and cultured cells (Figure 2.2). 
A correlation matrix for all profiled samples revealed that for the majority 
of samples, liver tumor profiles displayed greater similarity despite 
differing parental cell line origins (Figure 2.3). To identify broadly 
relevant metastasis regulators, genes were considered as putative 
promoters of liver colonization if at least two shRNAs targeting a given 
gene were depleted in tumors derived from all three cell lines and both 
independent transductions. This analysis resulted in 556 candidate 
promoters of liver colonization (Figure 2.4). Using similar criteria, 719 
genes appeared to be required for survival in cultured cells, while 187 
genes were in common to both cultured cells and tumor cells (Figure 2.4).  
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Figure 2.2: Depletion of shRNAs from large-scale shRNA screen for 
promoters of liver metastasis 
Overview of shRNA depletion in liver tumors (a) and cultured cells (b). 
shRNAs were ranked based on peak median absolute deviation 
normalized z-score of log2(Tumor/T0) or log2(Passaged/T0). shRNAs absent 
in both tumor replicates or cultured cells are in black. P-values for absent 
shRNAs were derived by bootstrapping with 1000 random samplings.  
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Figure 2.3: Correlation matrix of shRNA screen samples 
Correlation matrix of shRNA-depletion profiles of samples using 
Spearman’s correlation coefficient. Clustering was performed in R using 
Euclidean distance and complete agglomeration method. SW = SW620, LS 
= LS174T, Wi = WiDr. 
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Figure 2.4: Genes with two or more shRNAs absent from screen samples 
Summary of absent shRNAs and gene hits from tumor (a) and cultured 
cells (b) in each cell line and in common to all cell lines. Percentage of total 
population is indicated in parentheses. (c) Overlap between gene hits 
scored in tumors and those scored in culture. 
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 To confirm that the analyzed shRNAs were effective in suppressing 
liver colonization, a secondary library was generated using top-scoring 
shRNAs that targeted the 556 genes. These top-scoring shRNAs as well as 
20 control shRNAs were cloned into the plko.1 expression vector and 
pooled to allow for equal representation in the library. This library was 
transduced into a highly metastatic in vivo-selected colon cell line, LS-
LVM3b (Loo et al., 2015). These populations were then subjected to the 
experimental procedures performed for the primary large-scale screen. 
This experiment revealed that these shRNAs were significantly depleted 
from tumors, confirming the technical efficacy (Figure 2.5). To better rank 
the candidate hits from the screen, genes were scored from the primary 
large-scale liver colonization screen by applying the RIGER algorithm, 
which ranks genes based on the number and relative depletion of 
targeting shRNAs and thus accounts for differences in the number of 
shRNAs per gene (Luo et al., 2008). These scores were used to generate 
gene percentile scores, providing a continuous scale to assess relative 
importance of genes. As expected, the top 556 candidate genes were 
significantly enriched among the top percentile scores, providing 
confidence in the candidate liver colonization gene list (Figure 2.5). 
 
  
 30 
 
Figure 2.5: Validation of scoring shRNAs and final scoring method 
(a) Distribution of shRNA depletion in tumors from secondary library 
using a scoring shRNA targeting each of the 556 top genes. (b) 
Distribution of 556 top genes as scored by RIGER and ranked by gene 
percentile. 
 
Identification of PKLR as a kinase required for liver colonization 
 Of the top-scoring 556 genes from the primary screen, kinases, 
which are known to mediate most of the signal transduction in eukaryotic 
cells (Manning et al., 2002) were focused on to allow for the identification 
of critical regulatory mechanisms. The top-scoring kinases from the 
RIGER gene ranking included many known regulators of colorectal cancer 
progression including IGF1R (Reinmuth et al., 2002) and DDR2 (Badiola et 
al., 2011), which, consistent with previous studies, displayed high gene 
percentile scores in the screen performed in cultured cells, indicative of 
roles in in vitro population growth (Figure 2.6). Surprisingly, one of the 
top-scoring genes was liver and red blood cell pyruvate kinase (PKLR), 
which had been commonly believed to be expressed only in liver, kidney, 
and red blood cells (Luo and Semenza, 2012). Interestingly, PKLR 
displayed a low gene percentile score under culture conditions, 
suggesting a specific requirement for this gene during liver colonization.  
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Figure 2.6: Gene percentile scores of top kinases from large-scale 
shRNA screen 
Kinases from top 556 candidate promoters were ranked by RIGER gene 
percentile score in liver tumor and cell culture large-scale screens. 
 
 
Fuctional validation of PKLR as promoter of metastatic liver colonization 
 To confirm these findings and account for potential off-target 
effects from the targeting shRNAs in the primary screen, LS174T cell lines 
were generated with additional independent PKLR-targeting shRNAs not 
previously used in the primary screen (Figure 2.7). PKLR expression was 
adequately depleted to the levels of 13% & 17% of control. Importantly, in 
concordance with the in vivo screen results, PKLR-depleted cells were 
significantly less effective than control cells in colonizing the liver 
following direct liver inoculation (Figure 2.7). Additionally, in vitro 
proliferation assays confirmed that PKLR depletion did not reduce 
population growth in culture and also did not reduce subcutaneous tumor 
growth (Figure 2.8). 
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Figure 2.7: PKLR promotes liver colonization 
(a) PKLR depletion as measured by quantitative RT-PCR in LS174T cells. 
(b) 5x105 LS174T cells were inoculated by direct liver injection, and liver 
colonization was measured by ex vivo bioluminescence after 20 days. 
Representative liver bioluminescence and gross histology are shown 
(n=6). P-values were derived using one-sided Mann Whitney test. 
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Figure 2.8: PKLR does not promote population growth in culture or 
subcutaneous tumor growth 
(a) 5x104 LS174T cells were seeded in triplicate and viable cells were 
counted by trypan blue exclusion after 5 days under recommended cell 
culture conditions. Data shown is from three independent experiments. 
(b) 106 LS174T cells were injected into mice subcutaneously and tumor 
volume was measured over time (n=6). 
  
 
 To validate this colonization defect in the context of metastasis, 
additional cell lines were generated with additional shRNAs targeting 
PKLR. In the highly metastatic LS-LVM3b cell line, PKLR expression was 
depleted to 9% of control, while in the SW620 cell line, PKLR expression 
was depleted to 58% and 42% of control (Figure 2.9). These cells were then 
inoculated via portal circulation to assess metastatic capacity upon 
hematogenous arrival in the liver. PKLR-depleted cells exhibited 
significantly decreased liver metastatic colonization capacity in metastasis 
assays (Figure 2.9). These results revealed PKLR to promote metastatic 
liver colonization of colon cancer cells. 
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Figure 2.9: PKLR promotes metastatic liver colonization 
PKLR depletion as measured by quantitative RT-PCR in LS-LVM3b (a) 
and SW620 cells (c). 5x105 LS-LVM3b (b) and SW620 (d) cells were 
inoculated by portal circulation injection and metastatic colonization was 
measured by liver bioluminescence after 20 days (n=14) for LS-LVM3b 
and 35 days (n=8) for SW620. Representative mouse bioluminescence, 
liver bioluminescence and gross histology are shown. P-values were 
derived using one-sided Mann Whitney test.  
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 To further characterize the role of PKLR in colonization, PKLR was 
assessed for whether it promoted colonization in the setting of the 
primary tumor before cancer cell dissemination. Cells were inoculated 
into the cecal wall of mice to model primary colorectal cancer tumor 
growth. PKLR depletion did not affect tumor growth under these 
conditions (Figure 2.10), indicating that PKLR provides an advantage 
selectively to metastatic growth.  
 
 
 
 
Figure 2.10: PKLR does not promote primary tumor growth  
106 LS174T cells were inoculated by cecal injection and tumor growth was 
monitored by in vivo bioluminescence over time (n=5).  Representative 
mouse bioluminescence at final time point are shown on the right.  
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2.3 Clinical relevance of PKLR expression 
PKLR expression in normal colon and colon cancer tissue 
In mammalian cells, pyruvate kinase is encoded by four isozymes: 
M1 (PKM1), M2 (PKM2), liver (PKL) and red blood cell (PKR). While the 
M1, L and R isozymes are described to exhibit tissue-specific expression, 
the pyruvate kinase M2 isoform is highly expressed across cancer types 
(Mazurek et al., 2005). Pyruvate kinase L and R have only been described 
in their respective tissues to promote glycolysis, catalyzing the final rate-
limiting step, which involves the transfer of a phosphate group from 
phosphoenolpyruvate (PEP) to ADP, generating pyruvate and ATP. 
Although PKLR had originally been described to be expressed solely in 
liver, kidney and red blood cells (Imamura and Tanaka, 1972), PKL 
expression has also been observed in epithelial cells in the intestinal 
epithelium of rats (Domingo et al., 1992; Osterman and Fritz, 1974). 
Analysis of the Human Protein Atlas data (Uhlen et al., 2010) revealed 
PKL mRNA expression in normal colon tissue and PKLR protein 
expression in normal colonic glandular tissue and colorectal cancer 
tumors (http://www.proteinatlas.org, Figure 2.11).  
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Figure 2.11: PKLR is expressed in normal colon and colon cancer tissue 
(a) RNA-sequencing read density at PKLR locus from normal colon tissue. 
PKL-specific exon is indicated with dashed box. (b) PKLR protein 
expression as measured by immunohistochemistry in normal colon and 
colorectal cancer tissue. Scale bar is 100um. 
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PKLR expression is associated with clinical liver metastasis 
To determine whether PKLR expression levels are associated with 
liver metastasis, PKLR transcript levels were compared in patient samples 
of primary tumors and liver metastases. Samples were obtained from 
patients at MSKCC to compare PKLR transcript levels in patient primary 
tumor and liver metastasis samples. In 70 samples, PKLR mRNA was 
significantly up-regulated in liver metastases relative to primary tumors 
(Figure 2.12c). This up-regulation was also observed in multiple 
independent datasets of unmatched (Figure 2.12a-b) and matched (Figure 
2.12d-e) colorectal cancer patient samples (Ki et al., 2007; Kikuchi et al., 
2013; Kim et al., 2014; Matsuyama et al., 2010; Sheffer et al., 2009; Stange et 
al., 2010; Watanabe et al., 2011). These samples were from a total of 311 
patients. Additionally, in primary tumors, increased PKLR expression was 
associated with the presence of metastatic disease as well as the 
development of liver metastases (Figure 2.13). These tumors totaled 284 in 
sum. Taken together, PKLR expression in human samples is consistent 
with a positive role for PKLR in the development of liver metastasis and 
in agreement with functional experimental data.  
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Figure 2.12: PKLR expression is increased in human liver metastases 
PKLR expression as measured by microarray (a), RNA-sequencing (b), 
and quantitative RT-PCR (c) in unmatched primary and liver metastasis 
tumors as shown by box plots. P-values were derived using one-sided 
Mann Whitney test unless otherwise indicated. Error bars represent SEM. 
(d)(e) PKLR expression as measured by microarray in matched primary 
and liver metastasis tumors. Increase in PKLR expression is indicated in 
red; decreased expression is indicated in gray. P-values were derived 
using paired one-sided t-test. *=P<0.05, **=P<0.01, ***=P<0.001 
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Figure 2.13: PKLR expression is increased in primary tumor samples 
from patients with metastases  
(a)(b) PKLR expression as measured by microarray in primary tumors of 
patients with or without metastases present at time of sampling. (c) PKLR 
expression as measured by microarray in primary tumors of patients who 
were monitored over time for the development of liver metastases. P-
values were derived using one-sided Mann Whitney test unless otherwise 
indicated. Error bars represent SEM. *=P<0.05 
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2.4 Cellular characterization of PKLR function 
PKLR promotes cell survival during colonization in vivo 
To characterize how PKLR promotes metastasis at the cellular level, 
two possibilities were considered. PKLR could function to promote cell 
growth and proliferation, or PKLR could function to prevent cell death. 
Since PKLR depletion had no effect on subcutaneous tumor growth or 
primary tumor growth (Figures 2.8, 2.10), PKLR knockdown cells were 
assessed for cell death in vivo. To assess cell death, an in vivo caspase-3/7-
dependent bioluminescence reporter (Hickson et al., 2010) was used to 
measure apoptotic cell burden during metastatic liver growth. At early as 
well as at late time points, apoptosis was significantly increased in PKLR 
knockdown cells (Figure 2.14). Calculation of cumulative apoptotic 
burden over time revealed a significantly elevated rate of apoptosis 
(Figure 2.14), suggesting that PKLR is required for continuous metastatic 
cell survival.  
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Figure 2.14: PKLR knockdown leads to increased cancer apoptosis 
(a) 5x105 SW620 cells were inoculated by portal circulation injection and 
apoptotic cell burden in the liver was monitored using DEVD-luciferin 
bioluminescence relative to live cell bioluminescence over time (n=5). P-
values were derived using one-sided Student’s t test. (b) Cumulative 
apoptotic/live cell burden over time was determined by calculating the 
area under the curve for each mouse. Linear regression lines are shown. P-
values were derived using ANCOVA testing for difference in slope.  
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To confirm these findings, livers were extracted and processed to 
visualize apoptotic markers in tumor nodules. PKLR-depleted cells 
exhibited significantly fewer tumor nodules per liver (Figure 2.15), 
confirming our original assessments by gross histology. Interestingly, 
while tumor nodules generated from control cells appeared to be highly 
cellular, the majority of PKLR-depleted tumor nodule cores appeared 
devoid of cells and composed of extracellular cleaved caspase-3 (Figure 
2.15). While the reduced number of tumor nodules indicates the 
importance of PKLR in early colonization, enhanced apoptosis in tumor 
cores suggested a pathophysiological requirement for PKLR function 
during later stages of metastatic colonization.  
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Figure 2.15: PKLR knockdown metastatic nodules display increased 
apoptosis in tumor core 
(a) 5x105 SW620 cells were inoculated by portal circulation injection; after 
28 days, livers were resected, and nodules per liver section was quantified 
(n=4). The average of three liver sections for each mouse was used. (b) For 
each liver, proportion of the indicated nodule type is shown. P-values 
were derived using two-sided Fisher’s exact test on total nodule count for 
each PKLR shRNA compared to shControl. (c) Representative images of 
nodule types. Luciferase and human Vimentin were used to label cancer 
cells. Inset shows higher magnification. Scale bars = 50um.  
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PKLR promotes cell survival under hypoxia and high cell density in vitro 
The tumor core represents a distinct microenvironment with 
limited nutrient supply, unique stromal composition, and altered cell-to-
cell architecture (Quail and Joyce, 2013). Liver metastases are susceptible 
to stress-induced apoptosis (Bao et al., 2004) and demonstrate variable 
angiogenic capacity (Vermeulen et al., 2001), suggesting that cancer cells 
farther from vasculature may be especially sensitive to nutrient and 
oxygen deprivation. PKLR may be required for survival when cancer cells 
are subject to cellular stressors specific to the tumor core. To identify 
potential stressors, PKLR knockdown cells were grown under various 
conditions in vitro and were found to exhibit no survival defects under 
physiologic levels of glucose, hypoxia (1% O2), anoxia (<0.01% O2), high 
cell density, or low pH (Figure 2.16). Moreover, PKLR-depleted cells did 
not exhibit defects in well-established pro-metastatic phenotypes 
including Matrigel invasion capacity, anchorage-independent growth, and 
migration (Figure 2.16).  
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Figure 2.16: PKLR does not promote survival under various in vitro 
conditions 
Cells were seeded in triplicate under the following conditions: (a) 105 cells 
in 5.6mM glucose for 5 days, (b) 105 cells in 5.6mM glucose & hypoxia for 5 
days, (c) 106 cells in anoxia for 3 days, (d) 106 cells seeded at a density of 
1000 cells/mm2 for 3 days, (e) 105 cells in media buffered at pH 6.6 for 5 
days, (f) 25x103 cells in quadruplicate in invasion chambers and were 
allowed to invade for 48 hours, (g) 5x103 cells seeded in soft agar for 14 
days. Data shown is from three independent experiments. (h) 106 cells 
seeded overnight and scratched using a pipette tip the next day. Cells 
were seeded in duplicate and imaged daily. 
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While individual stressors elicited no phenotypic defect alone, the 
tumor core features multiple stressors that simultaneously impact cancer 
cells. To better recapitulate the microenvironment in the tumor core, cells 
were concurrently seeded at high cell density and in hypoxia. Under these 
conditions, PKLR knockdown populations displayed reduced survival—
decreased number of live cells and concurrently increased number of dead 
cells (Figure 2.17). To characterize whether the survival defect occurs 
continuously or whether nutrient depletion led to a population collapse, 
cells were assayed daily for viability under high cell density and hypoxia. 
Cells with reduced PKLR expression began to display a survival defect 
after as early as one day under these conditions, suggesting that the effect 
is continuous (Figure 2.17). Given the increased apoptosis rate observed in 
PKLR-depleted tumors, cells were assessed for apoptosis and necrosis by 
flow cytometry after one day under concurrent high cell-density and 
hypoxia. PKLR depleted cells exhibited fewer live cells, greater proportion 
of early apoptotic cells, and significantly greater proportion of late 
apoptotic cells under this condition (Figure 2.17). These results indicated 
that PKLR functions to enhance cell survival under cell-dense, hypoxic 
conditions, appropriately simulating pathophysiological features 
pertaining to metastatic growth in the liver. 
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Figure 2.17: PKLR promotes survival under conditions of hypoxia and 
high cell density 
(a) 106 LS174T cells were seeded in triplicate at a density of 1000 cells/mm2 
and were allowed to grow for 5 days in 1% O2. Live and dead cells 
discriminated using trypan blue. Data shown is from four independent 
experiments. (b) 106 LS174T cells were seeded in triplicate at a density of 
1000 cells/mm2 and were allowed to grow in 1% O2. Live cells were 
quantified using trypan blue exclusion. Data shown is from three 
independent experiments. 106 LS174T (c) and SW620 (d) cells were seeded 
at a density of 1000 cells/mm2 and were assessed for apoptosis after 24 
hours in 1% O2. P-values were derived using one-sided Student’s t test.   
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2.5 Molecular characterization of PKLR function 
Identification of binding partners of PKL and PKR
Interestingly, the in vitro survival defect of PKLR-depleted cells was 
observed using cell culture media supplemented with excess pyruvate, 
which can be readily imported into cells (Garcia et al., 1994)—arguing 
against the canonical glycolytic function of PKLR in these colon cancer 
cells. To determine whether PKLR could be functioning non-canonically, 
independent of its pro-glycolytic role, PKL and PKR binding partners 
were identified in colorectal cancer cells using tagged proteins for co-
immunoprecipitation experiments since commercial and custom 
antibodies were inadequate for the recognition of endogenous PKLR 
proteins in cell lysates. Immunoprecipitation of PKL and PKR followed by 
mass spectrometry revealed similar protein binding profiles and binding 
to many glycolytic enzymes (Figure 2.18, Table 2.1, Table 2.2), consistent 
with the role of pyruvate kinase in a glycolytic enzyme complex that 
allows for efficient lactate production (Mazurek, 2011).  
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Figure 2.18: Mass spectrometry analysis of PKL & PKR co-
immunoprecipitated proteins 
LC-MS/MS ion scores of FLAG-PKL and FLAG-PKR co-
immunoprecipitated proteins relative to empty vector in LS-LVM3b. 
Pearson’s correlation coefficient is shown. 
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Table 2.1: Top gene sets scored by Gene Set Enrichment Analysis of 
FLAG-PKL binding partners as measured by mass spectrometric 
quantification 
Table 2.2: Top gene sets scored by Gene Set Enrichment Analysis of 
FLAG-PKR binding partners as measured by mass spectrometric 
quantification 
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Interestingly, one of the most abundant binding partners identified 
was PKM, with multiple peptides matching specifically to the M2 isoform 
(Table 2.3, Figure 2.19)—the predominant isoform observed in colorectal 
cancer tissue and the only isoform observed to be expressed in the cell 
lines used (Bluemlein et al., 2011; Christofk et al., 2008a; Thangaraju et al., 
2009). Immunoprecipitation of tagged PKL or PKR revealed an association 
with endogenous PKM2 (Figure 2.19). Moreover, immunoprecipitation of 
endogenous PKM2 revealed PKM2 to associate with endogenous PKL 
(Figure 2.19). This suggested the formation of a pyruvate kinase hybrid 
complex (Saheki et al., 1978).  
Table 2.3: PKM2-specific peptides as measured by mass spectrometric 
quantification  
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Figure 2.19: PKL binds to PKM2 in colon cancer cells 
(a) Cell lysates from LS-LVM3b cells with indicated overexpression 
constructs were subjected to immunoprecipitation using anti-FLAG beads 
followed by LC-MS/MS. Protein peptide spectrum matches as compared 
to label free quantitation protein enrichment (relative to empty vector 
immunoprecipitation) is shown. (b) Cell lysates from LS-LVM3b cells 
were subjected to immunoprecipitation using anti-FLAG beads followed 
by western blot analysis. (c) Cell lysates from LS174T cells were subjected 
to immunoprecipitation using anti-HA beads followed by western blot 
analysis. 20 ng of recombinant PKL (rPKL) and PKR (rPKR) were 
analyzed as controls (dashed border). 
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PKLR negatively regulates PKM2 pyruvate kinase activity 
Given the differing biochemical properties of pyruvate kinase 
isozymes and the tetrameric structure required for maximal enzymatic 
activity (Mazurek, 2011), PKL could function to alter PKM2 pyruvate 
kinase activity. To test this hypothesis, PKLR-depleted cells were grown in 
cell-dense, hypoxic conditions and were subject to immunoprecipitation of 
PKM2 complexes. PKM2 complexes isolated from PKLR-depleted cells 
exhibited enhanced pyruvate kinase activity relative to control cells 
(Figure 2.20), indicating that PKLR negatively regulates PKM2 pyruvate 
kinase activity. Additionally, whole cell lysates from PKLR-depleted cells 
displayed an increase in total pyruvate kinase activity as well as decreased 
phosphoenolpyruvate-to-pyruvate ratio, consistent with decreased 
reaction substrate and increased reaction product driven by increased 
catalytic activity, following incubation under hypoxic, cell-dense 
conditions (Figure 2.20). These findings revealed that in colon cancer cells, 
PKLR expression can be utilized to negatively regulate PKM2 pyruvate 
kinase activity and deregulate metabolism to allow for cancer progression. 
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Figure 2.20: PKLR negatively regulates PKM2 pyruvate kinase activity 
(a) Immunoprecipitated PKM2 complexes from LS174T cells, subjected to 
16 hours in high cell-density and hypoxia, were assayed for pyruvate 
kinase activity. Activity was normalized to immunoprecipitated HA-
PKM2 as measured by western blotting. Data shown is from three 
biological replicates. P-value was derived using two-sided Student’s t test. 
Pyruvate kinase activity was measured from LS174T (b) and SW620 (c) 
cell lysates after 24 hours under hypoxic, cell-dense conditions. Activity 
was normalized to live cells. P-values were derived using one-sided 
Student’s t test. Data shown is from six biological replicates and two 
independent experiments. (d) Pyruvate levels and phosphoenolpyruvate 
(PEP) levels were measured from LS174T cell lysates after 24 hours under 
hypoxic, cell-dense conditions. P-value was derived using one-sided t-test. 
Each experiment was performed in triplicate. Data shown is from four 
independent experiments. 
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PKLR increases glutathione levels  
 PKM2 is essential for aerobic glycolysis observed in cancer cells, 
which leads to preferential lactate production and decreased 
mitochondrial metabolism (Christofk et al., 2008a). Previous studies have 
demonstrated an advantage conferred by decreasing PKM2 activity in 
cancer cells, namely the diversion of metabolic flux towards anabolic 
pathways, which promote biosynthetic processes (Christofk et al., 2008b; 
Lunt et al., 2014) and intracellular reducing power under oxidizing 
conditions through the pentose phosphate pathway (Anastasiou et al., 
2011). Because PKLR knockdown cells demonstrated no proliferative 
defect under oxygenated conditions (Figure 2.8) as seen with impaired 
biosynthetic processes, PKLR knockdown cells were assessed for 
depletion of intracellular glutathione, the main cellular antioxidant 
(Franklin et al., 2009), under hypoxic, cell-dense conditions. Indeed, PKLR 
knockdown cells demonstrated decreased glutathione levels (Figure 2.21).  
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Figure 2.21: PKLR increases glutathione levels 
Glutathione levels were measured using ThiolTracker from LS174T (a) 
and SW620 (b) cell lysates after 24 hours under hypoxic, cell-dense 
conditions. P-values were derived using one-sided t-test. Data shown is 
from three biological replicates. 
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Restoration of glutathione levels in PKLR-depleted cells rescues metastatic 
survival 
To confirm glutathione depletion is responsible for the cell survival 
defect, supplementation with molecules that can restore glutathione levels 
should rescue cell survival under hypoxic and cell-dense conditions as 
well as metastatic colonization. PKLR knockdown cells incubated in 
hypoxic and cell-dense conditions were supplemented with the 
antioxidant N-acetyl cysteine (NAC), a pro-drug to a glutathione 
precursor, and glutathione-monoethylester (GSH-MEE), a membrane-
permeable glutathione analog as glutathione does not readily cross the cell 
membrane. Treatment with these compounds rescued cell viability and 
decreased apoptosis in PKLR-depleted cells in vitro (Figure 2.22). 
Consistent with these in vitro findings, treatment of mice bearing PKLR 
knockdown cells with NAC in the drinking water partially rescued 
metastatic liver colonization and nearly completely restored the apoptosis 
rate to the levels of control cells (Figure 2.23). 
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Figure 2.22: Restoration of glutathione levels rescues cell survival in 
vitro 
LS174T (a) and SW620 (b) cells were assayed after 24 hours under 
hypoxic, cell-dense conditions for live and apoptotic cells by flow 
cytomentry. N-acetyl cysteine (NAC) and glutathione-monoethylester 
(GSH-MEE) were added to culture medium. P-values were derived using 
one-sided t-test. Data shown is from three biological replicates. 
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Figure 2.23: Restoration of glutathione levels rescues metastatic survival
(a) 5x105 SW620 cells were inoculated by portal circulation injection, mice 
were treated with NAC or control drinking water, and metastatic 
colonization was measured by liver bioluminescence after 35 days (n=5). 
P-values were derived using one-sided Mann Whitney test. 
Representative mouse bioluminescence, liver bioluminescence and gross 
histology are shown. (b)(c) Apoptotic cell burden was monitored by 
DEVD-luciferin liver bioluminescence relative to total live cell 
bioluminescence over time. Day 14 is shown in (c). (d) Cumulative 
apoptotic/live cell burden over time was determined by calculating the 
area under the curve for each mouse. Linear regression lines are shown. P-
values were derived using ANCOVA testing for difference in slope. 
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2.6 Therapeutic inhibition of glutathione synthesis 
GCLC expression is associated with liver metastasis in patients 
Given the susceptibility of liver metastases to glutathione 
depletion, glutathione synthesis might serve as a critical pathway utilized 
for metastatic progression. GCLC, the catalytic subunit of glutamate 
cysteine ligase, is responsible for the rate-limiting reaction of glutathione 
synthesis (Griffith, 1999) and thus, would be an appropriate molecular 
target for therapeutic inhibition. To determine whether GCLC may play a 
role in colorectal cancer metastasis to the liver, transcript expression levels 
were analyzed in patient samples. GCLC expression levels were found to 
be significantly higher in human colorectal cancer liver metastases relative 
to primary tumors (Figure 2.24). 
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Figure 2.24: GCLC expression is increased in human liver metastases 
GCLC expression as measured by RNA-sequencing (a) and microarray (b) 
in unmatched primary and liver metastasis tumors as shown by box plots. 
P-values were derived using one-sided Mann Whitney test. (c) GCLC 
expression as measured by microarray in matched primary and liver 
metastasis tumors. Increase in GCLC expression is indicated in red; 
decreased expression is indicated in gray. P-values were derived using 
paired one-sided t-test.  
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Functional validation of GCLC as promoter of liver metastasis 
To determine if GCLC is functionally required for metastasis in a 
manner consistent with the cell survival function of PKLR, functional 
studies were performed using cells depleted of GCLC by RNAi. GCLC 
expression was depleted to 27% & 13% of control in LS174T cells and 41% 
& 26% of control in SW480 cells (Figure 2.25). Functional studies in vitro 
revealed GCLC to be required for cell survival under hypoxia and cell-
dense conditions (Figure 2.25). Functional studies in vivo revealed GCLC 
to be required for metastatic liver colonization and to suppress cancer cell 
apoptosis (Figure 2.26), consistent with the observed phenotypes seen 
with PKLR knockdown.  
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Figure 2.25: GCLC promotes survival under conditions of hypoxia and 
high cell density 
GCLC knockdown as measured by qRT-PCR in LS174T cells (a) and 
SW620 (c). 106 LS174T (b) and SW480 (d) cells were seeded at a density of 
1000 cells/mm2 and were assessed for apoptosis after 24 hours in 1% O2. P-
values were derived using one-sided Student’s t test.  
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Figure 2.26: GCLC promotes metastatic liver colonization 
5x105 LS174T (a) and SW480 (c) cells were inoculated by portal circulation 
injection and metastatic colonization was measured by liver 
bioluminescence after 21 days (LS174T) or 30 days (SW480). 
Representative mouse bioluminescence, liver bioluminescence and gross 
histology are shown. n=5. (b) DEVD-luciferin bioluminescence relative to 
live cell bioluminescence was measured in the liver at day 7 (n=5). P-
values were derived using one-sided Student’s t-Test. 
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Small molecule inhibition of GCLC suppresses metastasis 
The findings that GCLC promotes metastatic colonization 
suggested that small molecules that block glutathione synthesis may 
exhibit metastasis-suppressive effects (Schulze and Harris, 2012). To test 
this hypothesis, colon cancer cells were first inoculated into the portal 
circulation of mice, and then L-buthionine-(S,R)-sulfoximine (BSO), a 
small molecule inhibitor of GCLC (Griffith, 1982), was added to the 
drinking water. Therapeutic delivery of BSO suppressed metastatic 
colonization and increased cancer cell apoptosis in colon cancer cell lines 
(Figure 2.27). Additionally, BSO suppressed metastasis of a primary cell 
line recently obtained from a patient’s colorectal cancer tumor and 
passaged in mice (Figure 2.28). These results highlight the importance of 
cancer cell glutathione levels for metastatic survival in the liver and 
identify this metabolic pathway as a viable therapeutic target. 
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Figure 2.27: BSO suppresses metastasis in colon cancer cell lines 
5x105 LS174T (a) and SW480 (c) cells were inoculated by portal circulation 
injection, and mice were provided BSO in drinking water. Metastatic 
colonization was measured by liver bioluminescence after 28 days 
(LS174T) or 35 days (SW480). Representative mouse bioluminescence, 
liver bioluminescence and gross histology are shown. n=5. (b) DEVD-
luciferin bioluminescence relative to live cell bioluminescence was 
measured in the liver at day 7 (n=5). P-values were derived using one-
sided Student’s t-Test. 
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Figure 2.28: BSO suppresses metastasis in primary colon cancer cell line 
7.5x105 CLR1 cells were inoculated by portal circulation injection, and 
mice were provided BSO in drinking water. Metastatic colonization was 
measured by liver mass after 28 days. Representative gross histology is 
shown. n=8.  
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2.7 Discussion 
Glycolytic deregulation in cancer 
Metabolic deregulation has recently emerged as a hallmark of 
cancer (Cairns et al., 2011; Hanahan and Weinberg, 2011; Kaelin and 
McKnight, 2013). Following Warburg’s observation of cancer cell 
dependence on aerobic glycolysis (Warburg, 1956), molecular dissection of 
glycolytic control has revealed the proliferative benefits of gene 
expression changes under hypoxia as well as metabolite diversion 
(DeBerardinis et al., 2008; Semenza, 2007; Vander Heiden et al., 2009). The 
pyruvate kinase M2 isoform enzymatic catalysis is a key regulatory event 
for glycolysis, controlling both glycolytic flux for energy demands and 
flux towards biosynthetic pathways of nucleotides, amino acids, and 
reducing power for cancer cell proliferation and antioxidant generation 
(Anastasiou et al., 2011; Chaneton et al., 2012; Christofk et al., 2008a; 
Christofk et al., 2008b). Cancer cells take advantage of this regulation—
PKM2 pyruvate kinase activity can be inhibited through destabilized 
subunit interactions and resultant loss of homotetramer structure, which 
is required for maximum enzymatic activity (Vander Heiden et al., 2009). 
Our findings reveal that colon cancer cells utilize an additional means of 
PKM2 regulation, namely expression of an additional isozyme PKL.  
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Utilization of pathways endogenous to metastatic niche 
The advantageous expression of liver-specific pyruvate kinase in 
cancer cells to allow for metastatic growth in the liver suggests that 
Paget’s ‘seed and soil’ hypothesis can be explained in part by cancer cell 
utilization of pathways endogenous to cells at the metastatic niche (Fidler, 
2003). The PKL isozyme is essential for hepatocytes as the sole enzyme for 
glycolytic pyruvate production and regulated flux through alternative 
pathways. This importance is highlighted by regulation of hepatic PKL 
activity and expression in response to glucagon, insulin and dietary 
carbohydrates (Yamada and Noguchi, 1999). Since hepatocytes experience 
significant oxidative stress as a result of hypoxemic blood supply and 
xenobiotic metabolism (Jungermann and Kietzmann, 1996), antioxidant 
supply and controlled flux towards glutathione regeneration is likely 
critical for hepatocyte survival and function. Future studies into the 
regulatory role of PKL in hepatocytes will clarify this enzyme’s function in 
normal physiology. While early metastatic colonization can be achieved 
through utilization of organ-specific nutrients (Loo et al., 2015), cancer cell 
activation of pathways endogenous to the metastatic niche appears to 
contribute to continued progression of metastatic colonies.  
Whereas the liver actively promotes high pentose phosphate 
pathway activity in mammals (Cabezas et al., 1999), colon cancer cells 
modulate glycolysis through expression of PKLR, consistent with the 
enhancement of pentose phosphate pathway flux and regeneration of 
glutathione required for survival in the liver. The importance of 
glutathione levels is highlighted by further, independent promotion of 
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glutathione levels: increased expression of GCLC, the rate-limiting 
reaction in glutathione synthesis. While GCLC and PKLR function 
appears to be critical regulatory steps that are broadly utilized by colon 
cancer metastases as suggested by clinical expression association, other 
mechanisms may be additionally utilized to ensure sustained glutathione 
levels such as activation of hepatocyte glutathione efflux to allow for the 
import of glutathione precursors from plasma (Obrador et al., 2011). 
Nevertheless, glutathione levels appear critical for metastatic cell survival 
and represent a potential clinical target. 
 
Therapeutic potential of metabolic modulation 
 Therapeutic inhibition of glutathione synthesis can suppress liver 
colonization through increasing cancer cell apoptosis, suggesting that 
targeting this pathway has potential to induce cell death of already-
formed metastatic nodules. BSO has been previously tested in a phase I 
clinical trial on a variety of advanced cancers as an adjuvant and has 
demonstrated both significant glutathione suppressive activity as well as 
minimal toxicity (Bailey et al., 1997). Additionally, the development of 
more potent inhibitors of GCLC may allow for enhanced efficacy 
(Tokutake et al., 1998). Given that small-molecule activation of PKM2 is 
being investigated as a strategy to suppress tumor growth (Anastasiou et 
al., 2012), the findings presented here suggest that glycolytic activation 
might display additional apoptotic effects in liver metastasis. The poor 
survival of patients with metastatic disease and the need for therapies 
specific to metastasis warrants further development of metabolic 
modulation as a therapeutic approach.  
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2.8 Materials and Methods 
Cell culture 
LS174T, LS-LVM3b, SW620, SW480, and WiDr cell lines were propagated 
as previously described (Loo et al., 2015) and were obtained from ATCC 
except for in vivo-selected LS-LVM3b derived in the laboratory. All cell 
lines were labeled with luciferase reporter construct for in vivo 
bioluminescent monitoring (Hickson et al., 2010). LS174T, LS-LVM3b, and 
WiDr cell lines were maintained in DMEM media supplemented with 10% 
FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. SW620 
and SW480 were maintained in McCoy’s media  supplemented with 10% 
FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. The 
cell lines used were selected to represent the mutational spectrum most 
commonly seen in patients (Kras wild-type/mutant, Braf wild-
type/mutant, MSS/MSI). Cells in culture were routinely tested for 
mycoplasma contamination. Standard cell culture conditions for these cell 
lines are considered to be cell seeding at a density of approximately 50-100 
cells/mm2, growth at 37°C and 5% CO2, and dissociation and dilution of 
cells before reaching confluency.  
shRNA screening 
10 subpools of lentiviral particles from the TRC1 human shRNA pooled 
library (Sigma), consisting of 71,444 shRNA clones representing 14,523 
genes, were transduced into luciferase-expressing LS174T, WiDr and 
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SW620 colon cancer cell lines. Two transductions for each cell line were 
performed as biological replicates at a low titer (MOI < 1) to reduce the 
likelihood of multiple shRNAs in a single cell. Transductions were 
performed with 8ug/ml of Polybrene (Millipore) to enhance efficiency. 48 
hours after transductions, puromycin was added at a concentration of 
2ug/ml until un-transfected cells died to select for cells with stable 
integrants. After antibiotic selection, the remaining cells were allowed to 
recover for a week prior to subsequent experiments. A portion of the 
selected cells were set aside and genomic DNA extracted. This is the 
reference pool of genomic DNA prior to the selective pressure of liver 
colonization. A second population of the cells was used for in 
vivo experiments, while a third was kept in culture for the duration of 
the in vivo experiment. For direct liver injections, 800K cells from each 
transduced population containing a single subpool was inoculated into an 
average of 7 mice, summing to 204 mice in total for all subpools and cell 
lines and allowing for a 783x depth of coverage. After 3 to 4 weeks when 
tumors had developed as measured by bioluminescence (approximately 
109-1010 photons/s), mice were sacrificed, and tumors were resected. Cells 
from the various conditions were processed by isolation of genomic DNA 
using DNeasy kit (Qiagen). A total of 5ug of genomic DNA isolated from 
tumors from different mice were pooled and PCR amplification of shRNA 
inserts was performed using 10 reaction tubes and pooled. A first 
amplification was performed using touchdown PCR ( Fwd_rd1: 
TGGACTATCATATGCTTACCGTAACT;Rev_rd1: 
AAAGAGGATCTCTGTCCCTGT.  The PCR product from all 10 reactions 
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(~350 bp) were gel-purified and pooled. Subsequently, a second round of 
amplification was performed with Illumina-sequencing specific primers 
(Fwd_rd2: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCTGTATTCTTGGCTTTATATATCTTGTGGA
AAGGAC, 
Rev_rd2: CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGGATG
AATACTGCCATTTGTCTCGAGGTCGA). The subsequent PCR product 
was gel purified (~300bp) in preparation for high-throughput sequencing 
on Illumina HiSeq2000. Once the sequencing results were obtained, the 
data was filtered to normalize samples by total reads and to remove 
shRNAs that were not included in all reference samples. 54,591 shRNA 
clones representing 14,095 genes were used in the final data analysis. For 
each sample, shRNA ratios to the reference cell line were calculated, and 
z-scores were calculated using peak median absolute deviation (PMAD) 
(Luo et al., 2008) to normalize for the global loss of shRNAs under these 
experimental conditions. Given the effects of off-target RNAi silencing, 
genes were scored as hits only if at least two shRNAs in each cell line were 
absent from the final tumor samples in both independent transduction 
replicates. The secondary library was generated by cloning a top-scoring 
shRNA from the large-scale screen into plko.1 and producing a viral 
library that was subjected to the experimental procedures listed above. 
Gene scoring by RIGER algorithm was performed using weighted-sum 
method on shRNAs in all cell lines. Gene ranking was averaged across cell 
lines, which was then used to calculate gene percentile. To identify 
kinases, genes from the top 556 hits were selected if annotated as a kinase 
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by GO annotation KINASE_ACTIVITY (GO: 0016301) and mean depletion 
in the secondary screen was greater than 2 z-scores. These kinases were 
then assessed for their gene percentile score by RIGER. 
 
Stable cell lines 
Virus was generated using ViraSafe lentiviral packaging system (Cell 
Biolabs). shRNA plasmids used were obtained from Sigma TRC library. 
Indicated shRNAs (Sigma) are as follows: shControl (SHC002), PKLR sh83 
(TRCN0000006383), PKLR sh84 (TRCN0000006384), PKLR sh39 
(TRCN0000199139), PKLR sh40 (TRCN0000194740), GCLC sh64 
(TRCN0000333564), and GCLC sh62 (TRCN0000344862). Because shRNAs 
displayed varying efficacy depending on the cell line used, shRNAs used 
for experiments were selected among multiple for the best-depleted 
efficiency. To generate overexpression, N-terminal FLAG tag or HA tag 
was added to cDNA of PKL/PKR or PKM2, respectively, and cloned into 
pBabe-Puro or pBabe-Hygro expression vector. Transductions were 
performed with 8ug/ml Polybrene (Millipore). 
 
Animal studies 
Animal experiments were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at The 
Rockefeller University. NOD-SCID male mice, aged 6 weeks, were used in 
experiments involving direct liver injections and LS-LVM3b cells. NOD-
SCID gamma male mice, aged 6-8 weeks, were used in all other 
 76 
experiments. For direct liver injections, cells in PBS were mixed with 
Matrigel (Corning) at a 1:1 ratio and injected with a total volume of 20ul 
into the most anterior lobe. For subcutaneous injections, cells in PBS were 
mixed with Matrigel (Corning) at a 1:1 ratio and injected with a total 
volume of 100ul bilaterally near hind limbs. For portal circulation 
injections, cells in PBS were injected into the spleen with the direction of 
circulatory flow in a volume of 50ul. After 30 seconds to allow for 
complete exit of cells from spleen, the spleen was removed by cautery. For 
cecal injections, cells in PBS were mixed with Matrigel (Corning) at a 1:1 
ratio and injected with a total volume of 20ul into the cecal wall. To 
monitor tumor burden, mice were inoculated with 1.67mg D-luciferin 
(Perkin Elmer) in 100ul by suborbital injection, and photon flux was 
immediately measured in IVIS Lumina System (Perkin Elmer). 
Bioluminescence was performed immediately following cell inoculation 
with an exposure time of 5 min and weekly thereafter unless otherwise 
noted with an exposure time of 1 min. Tumor burden over time between 
groups was performed by normalizing to matched bioluminescence signal 
immediately following cell inoculation. To monitor apoptosis, mice were 
inoculated with 0.83mg of Z-DEVD-aminoluciferin (VivoGlo Caspase 3/7 
Substrate, Promega) in 100ul by suborbital injection, and photon flux was 
immediately measured with an exposure time of 5 minutes in IVIS 
Lumina System as a measure of early apoptotic cells. 3 hours later, total 
tumor burden was measured using D-luciferin as described above. 
Relative apoptotic cell burden at a given time point was calculated by 
taking the ratio of bioluminescence signal obtained using Z-DEVD-
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aminoluciferin over the bioluminescence signal obtained with D-luciferin. 
To calculate an apoptosis rate, for each mouse, the relative apoptotic cell 
burden was plotted over time, and the area-under-the-curve (AUC) was 
calculated between t=0 and each time point. The calculated AUC data 
points were plotted over time, and a linear regression was performed. For 
N-acetyl cysteine treatments, mice were providing 40mM NAC drinking 
water with the pH matched to control water and the solution replaced 
twice weekly. BSO treatment studies were performed by supplying BSO 
in drinking water at 20mM, a dose previously demonstrated to display no 
significant toxicities in mice (Watanabe et al., 2003), and the solution was 
replaced twice weekly. Mice were randomized following cancer cell 
inoculation and prior to treatment. 
Patient-derived primary colon cancer graft 
CLR1 was derived from the liver metastasis of a subject with recurrent 
rectal adenocarcinoma with a KRAS G12 mutation.  Within two hours of 
surgical resection, tumor tissue not needed for diagnostic purposes was 
implanted subcutaneously into two NSG mice at the Antitumor 
Assessment Core at Memorial Sloan-Kettering Cancer Center.  When the 
tumor reached 1,000 mm3, mice were euthanized, tumor was excised, and 
a 100 mm3 piece of tumor tissue was reimplanted into another set of mice 
at Rockefeller University.  To maintain the xenograft line, the 
subcutaneous tumor was passaged each time the tumor reached 1,000 
mm3.  The cells used for the splenic injection of CLR1 had been passaged 
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subcutaneously six times prior.  To obtain a single-cell suspension for 
injection, mice were euthanized, and the subcutaneous tumor was excised 
and subjected to a series of mechanical and enzymatic separations to 
obtain a single-cell suspension.  Cells of mouse origin were depleted from 
the single-cell suspension via magnetic-activated cell sorting using the 
mouse depletion kit (Miltenyi Biotec), leaving only cells derived from 
human colorectal cancer.  
 
Quantitative RT-PCR 
RNA was extracted using total RNA isolation kit as indicated by 
manufacturer (Norgen Biotek). cDNA was generated using Superscript III 
(Invitrogen). Fast SYBR Green Master Mix (Life Technologies) was used to 
analyze samples on Applied Biosystems 7900HT. Expression was 
normalized to HPRT expression. Primers sequences are as follows: HPRT-
F: GACCAGTCAACAGGGGACAT, HPRT-R: 
CCTGACCAAGGAAAGCAAAG, PKLR-F: 
TGGGAAAACTGGGTGGGATGGATG,  
PKLR-R: GAAGGAAGCAGCCGGGGATTTGAC, GCLC-F: 
GACCCATGGAGGTGCAATTA , GCLC-R: 
AACCTTTGACAGTGGAATGAGA 
 
Clinical analysis 
The following datasets were used for analysis: GSE41258, GSE50760, 
GSE6988, GSE14297, GSE18105, GSE27854, and GSE14095. RNA-
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sequencing data was normalized to total reads per sample. Affymetrix 
microarrays were analyzed for PKLR expression using probe 210451_at, 
which displayed the highest counts.
Immunofluorescence of frozen sections 
Livers were harvested from mice, washed with PBS, and fixed in 4% 
paraformaldehyde overnight. The following day, livers were washed with 
PBS, submerged in 30% sucrose until fully saturated, and then frozen in 
OCT solution on dry ice and stored at -80 degrees Celsius. Frozen liver 
blocks were sliced on tissue microtome in 10um sections and treated with 
methanol:acetone on slides. Slides were stained with the following 
antibodies: anti-Luciferase (1:100, Pierce), anti-cleaved Capase-3 (1:1000, 
Cell Signaling), and anti-hVimentin (1:40, Vector laboratories). Fluorescent 
secondary antibodies (1:250, Invitrogen) were applied for labeling of 
primary antibodies. DAPI was added prior to mounting. Slides were 
imaged on Leica TCS SP5 system. 
Hypoxia and high cell density assay 
Hypoxia was performed using 1% O2, 5% CO2, 94% N2 mixed gas (Praxair) 
in a Modular Incubator Chamber (Billups-Rothernberg). High cell-density 
was defined as a seeding density of 1000 cells/mm2. Experiments were 
performed in 6-well or 12-well plates using 2mL and 1mL of media, 
respectively. 
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Flow cytometry 
All experiments were done after 24 hours under conditions of high cell-
density and hypoxia. Apoptosis was assessed using GFP-certified 
Apoptosis/Necrosis detection kit (Enzo Life Sciences). AnnexinV+ cells 
were considered apoptotic, and AnnexinV-, 7-AAD- cells were considered 
live. For rescue experiments, N-acetyl cysteine was pH adjusted to 7.4 and 
used fresh at 2.5mM. GSH-MEE (Sigma) was used at 1mM. For 
glutathione measurements, ThiolTracker Violet (Life Technologies) was 
used according to manufacturer’s instructions at 10uM and analyzed in 
combination with 7-AAD to exclude dead cells. Cells were analyzed on 
LSRII (BD). Analysis was performed on FloJo. Experiments were 
performed in biological triplicate and were repeated at least twice. 
 
Co-immunoprecipitation & western blotting 
Cells were lysed using 50mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 1% 
NP40, protease inhibitor (Roche), and phosphoSTOP (Roche). 
Immunoprecipitation was performed using anti-FLAG M2 magnetic 
beads (Sigma) or anti-HA magnetic beads (Pierce) for 1 hour at 4 degrees 
Celsius. For FLAG-based immunoprecipitation, beads were washed 2x 
with wash buffer containing 1M NaCl followed by a wash with wash 
buffer containing 50mM NaCl. For HA-based immunoprecipitation, beads 
were washed 2x with lysis buffer. Elution was performed using either 3x 
FLAG peptide (Sigma) or HA peptide (Pierce). Samples were reduced 
with reducing agent (Life Technologies), denatured, separated by SDS-
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PAGE, transferred to PVDF membrane (Pierce or Millipore), blocked with 
5% milk or 5% BSA, and probed with primary antibody. The following 
antibodies were used: anti-FLAG (1:1,000; Sigma), anti-PKM2 (1:1,000; Cell 
Signaling), anti-PKLR (1:75; Santa Cruz), and anti-HA (1:1,000; Cell 
Signaling). For PKM2 and HA detection, fluorescent secondary antibodies 
(1:10,000; Li-Cor) were used and detected on Odyssey SA Imaging System 
(Li-Cor). For PKLR and FLAG detection, antibodies were 
chemiluminescently detected using horseradish peroxidase–conjugated 
secondary antibodies (1:10,000), ECL2 Western Blotting Substrate (Pierce) 
and the SRX-101A (Konica Minolta) developer, according to the 
manufacturer’s instructions.  
Label Free Quantitation LC-MS/MS and analysis 
Co-immunoprecipitated and 3xFLAG eluted proteins were trypsinized in-
solution overnight. Peptides were desalted using home-made Empore C18 
columns prior to being analyzed by LC-MS/MS (Dionex 3000 HPLC 
coupled to Orbitrap XL, Thermo Scientific). Peptides were separated at 
300nL/min using a gradient increasing from 10% B to 45% B in 120 
minutes (A: 0.1% Formic Acid, B: Acetonitrile/0.1% Formic Acid). 
Generated LC-MS/MS data were queried against Uniprots complete 
Human Proteome (August 2013) and quantitated using MaxQuant 
1.5.0.30. In short, Peptide Spectrum Match false discovery rate was set to 
1% while protein false discovery rate was set to 1%. A total of 1,140 
proteins were matched. Match between runs were used for the label free 
 82 
quantitation. Generated label free quantitation values were analyzed 
using Perseus 1.5.0.9. All LFQ values were log2 transformed and filtered, 
requiring that a given protein displayed at least five matching peptides 
and three times as many peptide spectrum matches (PSMs). This resulted 
in 109 proteins. Absent LFQ values were replaced by a value one order of 
magnitude less. 
 
Pyruvate kinase assay 
106 LS174T cells were seeded in triplicate in 6-well plates in 1% O2 for 16 
hours. Immunoprecipitation was performed as described above for HA-
tagged proteins. Following elution of immunoprecipitated pyruvate 
kinase complex, PK activity was measured using lactate dehydrogenase 
(LDH)-coupled assay (Christofk et al., 2008b). Each reaction was 
performed under the following conditions: 50mM Tris, pH 7.5, 100mM 
KCl, 10mM MgCl2, 1mM PEP, 1mM ADP, 200uM NADH, 8 units LDH in 
50% glycerol, and 100uM FBP. Activity was normalized to 
immunoprecipitated HA-tagged PKM2 levels as measured by Li-Cor 
quantitative western blotting. Assay was monitored for pyruvate-
dependent conversion of NADH to NAD+ by fluorescence on Biotek 
Synergy Neo. For whole cell lysates, pyruvate kinase activity assay 
(Biovision) was used according to manufacturer’s instructions by 
fluorescent measurements. Activity was normalized to relative live cell 
proportion as measured by cell counting with trypan blue dead cell 
exclusion.  
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Pathway analysis 
Gene Set Enrichment Analysis (Subramanian et al., 2005) was performed 
on a list ranked by enrichment of proteins in FLAG-PKL/FLAG-PKR 
immuno-precipitated samples using the most abundant proteins relative 
to control based on the sum of peptide spectrum matches per protein. 
Curated C2 gene sets from version 4.0 of the MSigDB were used for 
analysis. 
Pyurvate assay 
3x106 cells were seeded in 60mm plate in triplicate and grown under 1% O2 
for 24 hours in recommended media without supplemental sodium 
pyruvate. Cells were washed with PBS containing 100uM phloretin and 
lysed and deproteinized using perchloric acid precipitation (Biovision). 
Pyruvate and PEP assays (Biovision) were used by fluorometric methods 
to quantify intracellular metabolite levels.  
Recombinant protein production 
PKL and PKR cDNAs were cloned into pGEX-6P-L vector, followed by 
transformation in BL21 (DE3) Gold (Agilent). 0.1mM IPTG was used to 
induce expression and after 3 hours, cells were lysed using 50mM Tris-
HCl, pH 7.5, 5mM EDTA, 200mM NaCl, 0.1% NP-40, 1mM DTT, 5mg/ml 
lysozyme and sonicated (Misonix Sonicator S-4000). Purification was 
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performed using glutathione-agarose beads (Sigma) and eluted using 
5mM reduced glutathione (Sigma). Cleavage of GST-tag was performed 
using Prescission protease (GE). 
 
Additional in vitro cell growth assays 
Anoxia was generated using the AnaeroPack System (Mitsubishi Gas 
Chemical). Cell culture under acidic pH was obtained by using MES 
buffer and adjusting to pH 6.6. Anchorage-independent growth was 
performed as follows: cells were suspended in 0.4% agar in cell culture 
media and layered on top of 0.6% agar in 24-well plates. Colonies formed 
with feed media changed every 4 days and were counted and imaged by 
light microscopy at 14 days. Invasion assays were performed by seeding 
cells on top of Matrigel invasion chambers (BD) and using light 
microscopy to image and quantify the number of cells that passed through 
to bottom well. 
 
Statistics 
Bootstrapping was performed by sampling with replacement in R. 
ANCOVA testing was performed using aov() command in R. Sample size 
in mice experiments was chosen based on biological variability observed 
with a given genotype. Non-parametric tests were used when normality 
could not be assumed. 
 
 
 
85 
CHAPTER 3: Highly Variable Cancer Subpopulations that Exhibit 
Metastatic Fitness and Transcriptomic Variability  
 86 
3.1 Introduction 
 
Non-genetic cell-to-cell variability in cancer 
 While the majority of intra-tumoral heterogeneity described to date 
focuses on genetic diversity, the mechanisms that govern non-genetic 
diversity remain poorly characterized.  Much of the challenge is due to 
the inherent genetic instability of cancer populations. As an individual 
tumor progresses over time, the genetic background changes with many 
beneficial as well as neutral mutations incorporated into the population. 
Additionally, the variation from patient-to-patient hampers clinical 
analyses and makes controlling for mutational differences nearly 
impossible.  
 However, there exist precedence for non-genetic mechanisms to 
contribute to cancer progression and metastatic growth. While 
chemotherapy resistance has been well-characterized to be mediated by 
genetic mutations in a number of cases (Gerlinger and Swanton, 2010), 
colorectal cancer clonal populations can display significant variability in 
the ability to form tumors and respond to chemotherapy despite stable 
genetic lineages over time (Kreso et al., 2013), suggesting non-genetic 
mechanisms as the source of molecular variability generation (Singer et 
al., 2014). Other studies have observed non-genetic cell-to-cell 
heterogeneity that enhances fitness of cells under cytotoxic conditions 
with chemotherapies (Gupta et al., 2011; Kreso et al., 2013; Sharma et al., 
2010; Spencer et al., 2009). Furthermore, molecular variability in the 
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dynamic response to chemotherapies can influence survival of cancer 
populations (Cohen et al., 2008).  
 It remains unclear whether non-genetic phenotypic diversity in 
cancer is molecularly regulated or whether it is simply biological noise 
(Marusyk and Polyak, 2010). Stochastic noise may be derived from 
inherently noisy processes such as transcription and translation (Brock et 
al., 2009). On the other hand, population heterogeneity in tumors can be 
driven by specific molecules that mediate subclonal interactions, 
balancing cell proliferation and cell competition (Marusyk et al., 2014). 
Further characterization of the mechanisms that govern phenotypic 
diversity will enable distinction between stochastic and deterministic 
noise. Nevertheless, non-genetic heterogeneity is an inherent yet currently 
poorly understood aspect in cancer that has the potential to enhance 
Darwinian evolution through increasing variability of a beneficial trait 
(Brock et al., 2009).  
 The clinical presentation of metastases suggests that metastatic 
progression may be driven in part by non-genetic mechanisms. The 
mutational status of metastatic tumor nodules fails to lend credence to 
genetic instability as the source of molecular diversity. Metastatic tumor 
nodules from breast, colorectal, and pancreatic cancers display a limited 
number of mutations, and of those found, none have been causally linked 
to the development of metastases (Ding et al., 2010; Jones et al., 2008; 
Yachida et al., 2010). Additionally, the amount of time needed to develop 
metastasis can be rapid, being as little as a year in the twenty-year lifespan 
of colorectal cancer (Jones et al., 2008). With multiple, independent, highly 
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selective steps in the metastatic cascade, it is unclear how a sufficient 
number of cancer-promoting mutations, which so far have not been 
detected by sequencing analyses, could contribute to this rapid cancer 
evolution. 
Clonal heterogeneity as a model for non-genetic variation 
The study of non-genetic variability was pioneered in bacterial 
systems because of the genetic homogeneity of strains. In 1976, Koshland 
demonstrated that individual E. coli cells displayed variable phenotypic 
responses to stimuli despite being genetically identical (Spudich and 
Koshland, 1976). Furthermore, clonal populations of E. coli allowed for 
quantification of biological noise at the molecular level in genetic lineages 
(Elowitz et al., 2002; Taniguchi et al., 2010). To study non-genetic 
variability in clonal cancer populations, genetic variation must be 
accounted for. This can be accomplished in part by limiting the number of 
cells divisions, thus reducing the potential contribution of functional 
genetic mutations to the population. Additionally, genomic analyses of 
cancer populations following clonal expansion would allow for an 
assessment of genomic integrity. This approach has been performed to 
characterize phenotypic variability of clonal colorectal cancer populations 
to form tumors and respond to chemotherapy (Kreso et al., 2013). 
Utilization of clonal analyses in cancer populations can allow for better 
understanding of the non-genetic variability that may be contributing to 
metastatic colonization. 
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3.2 Isolation of clonal subpopulations with enhanced diversification capacity 
 
Morphologic diversification 
 To generate an experimental model wherein genetic variation 
between cells is minimized so that non-genetic contributions to 
heterogeneity generation can be assessed, clonal subpopulations were 
derived from human cancer populations. The breast cancer cell lines 
MDA-MB-231 (MDA) and the minimally passaged CN34 breast cancer 
line (CN), both originally derived from the pleural effusion of patients 
with metastatic breast cancer (Bos et al., 2009; Cailleau et al., 1978) were 
seeded sparsely to allow individual cells to proliferate into isolated 
colonies. Once colonies could be visualized, these subpopulations were 
grown individually until cells could be seeded for microscopy. Nearly two 
hundred clonal subpopulations from these two cell lines were isolated.  
 Next, each subpopulation was assessed by microscopy to 
determine whether clonal populations could generate morphological 
variability following clonal expansion. Microscopic imaging was 
performed on cell populations labeled with CellMask stain to label entire 
cells and DAPI dye to label nuclei, and images were analyzed by 
automated image analysis to measure size parameters of individual cells, 
which include cell area, cytoplasmic area, nucleus size, perimeter, major 
axis length, and minor axis length. When cell size parameters were 
compared between subpopulations, there was significant inter-clonal 
variation (Figure 3.1). Namely, certain subpopulations consisted of large 
cells, while others consisted of primarily small cells.  
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Figure 3.1: Clonal subpopulations display inter-clonal variation 
Size parameters were measured for clonal subpopulations generated from 
MDA-MB-231 (a; n=98) and CN34 (b; n=97) breast cancer cell lines. 
Median, interquartile range, minimum, and maximum are depicted by 
box plots. Representative populations of small-sized and large-sized cell 
populations are shown; scale bars are 50um. CellMask red was used to 
label entire cells, while DAPI dye was used to label nuclei. 
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 To identify subpopulations that generate morphological variability, 
the distribution of cell size within a population was assessed by 
calculating the coefficient of variation for each size parameter. 
Furthermore, principal component analysis on the six coefficient of 
variation measurements was performed to generate a single linear 
measurement of intra-clonal variability. The majority of clonal 
subpopulations displayed a range of variability as assessed by using the 
first principal component—consistent with a single peak distribution 
(Figure 3.2). Notably, a few subpopulations demonstrated exceptionally 
high intra-clonal cell size variability without exhibiting significant 
differences in their population-level means (Figures 3.2, 3.3). These 
subpopulations served as candidates that have the capacity to generate 
phenotypic diversity. 
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Figure 3.2: Identification of subpopulations with high intra-clonal 
variation 
Histograms of the first principal component of size coefficient of variation 
(CV) was used to assess subpopulation size variability of MDA-MB-231-
derived clones (a) and CN34-derived clones (b). Candidate high 
variability populations are indicated in red. Representative images of high 
and low variability subpopulations are shown on the right. Scale bars = 
50um. 
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Figure 3.3: Variability in cell area in candidate high and low variability 
populations 
Distribution of cell area as shown from candidate high and low variability 
populations in MDA-MB-231-derived clones (a) and CN34-derived clones 
(b). Median, interquartile range, minimum, and maximum are depicted by 
violin plots.  
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Phenotypic diversification 
To determine if these subpopulations could give rise to and 
maintain phenotypic diversity beyond cell size, proliferative variability 
was assessed as an independent functional measure by colony formation 
assays. Cells from each subpopulation were seeded sparsely, allowed to 
grow into colonies, and then were stained with crystal violet to allow for 
macroscopic measurements. A macroscopically small colony would be 
indicative of a slower colony growth rate, whereas a large colony would 
indicate a faster colony growth rate. Thus, proliferative variability would 
manifest as both small and large colonies derived from the same 
subpopulation. Cell size and cell density within colonies were first 
assessed to confirm that these factors were not contributing to colony area 
differences (Figure 3.4).  
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Figure 3.4: Cell size and cell density are not responsible for colony area 
differences 
Representative images of cells in a colony from colony formation assay are 
shown; scale bar is 100um. 
 
 
 While bulk population growth in culture was observed to be 
similar between subpopulations (Figure 3.5), MDA-derived 
subpopulations that exhibited high intra-clonal size variability also 
displayed high variability in proliferative capacity, which could be 
visualized as high variability in colony sizes (Figure 3.6a). Among the CN-
derived populations, only subpopulation C57 displayed a modest increase 
in proliferative variability (Figure 3.6b), suggesting that the other 
morphologically variable subpopulations from this parental line may not 
exhibit variation of additional phenotypes beyond morphology.  
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Figure 3.5: Population growth in culture is not different between high 
and low variability subpopulations  
5x103 cells were seeded and assessed 72 hours later for viable cells using 
WST-1 reagent for MDA-MB-231-derived subpopulations (a) and CN34-
derived subpopulations (b). P-values were derived from two-sided 
student’s t-test (two-sample for MDA, one-sample for CN). 
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Figure 3.6: High variability subpopulations exhibit proliferative 
variability  
MDA-MB-231-derived colonies (a) and CN34-derived colonies (b) were 
grown in triplicate plates and measured for variability in colony area. 
Error bars indicate s.e.m. of three independent experiments. P-values were 
generated by testing Pearson’s correlation coefficient with two-sides. 
Representative images of colonies stained by with crystal violet and 
thresholded in ImageJ are shown on right; scale bar is 5mm. 
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 These subpopulations, herein referred to as high variability 
subpopulations, were next assessed for whether the observed variability 
was heritable. High variability (HV) and low variability (LV) 
subpopulations were seeded sparsely to allow for isolation of clonal 
progeny. These clonal progeny were expanded to allow for microscopic 
imaging of population cell sizes. High variability subpopulations 
maintained high cell size variability in progeny clonal subpopulations as 
compared to low variability subpopulations (Figure 3.7).  
 
 
 
 
 
 
 
 
Figure 3.7: Progeny from high variability subpopulations maintain size 
variability after clonal isolation and expansion 
Single cells isolated from indicated MDA-MB-231-derived (a) and CN34-
derived (b) subpopulations were expanded into clonal populations and 
were assessed for cell size variability. P-values were derived using two-
sided Mann Whitney U test. 
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 To further characterize cell size variability, a number of additional 
features were assessed. First, since size variability measured in two-
dimensions on cell culture plates could be due to either morphological 
shape or cell volume, high variability subpopulations were assessed for 
size variability in three-dimensions using ImageStream flow cytometry 
with high content image analysis. Indeed, high variability subpopulations 
exhibited size variability in three-dimensions (Figure 3.8), indicating 
variation in cell mass. Next, it is possible that cell size variability could be 
also attributed to altered cell cycle phasing as cells must grow in size prior 
to mitosis. Cell cycle phasing as measured by flow cytometric analysis of 
DNA content revealed no difference between high and low variability 
subpopulations (Figure 3.9). Finally, cell size variability was assessed for 
its robustness following passage in culture and growth at varying 
densities. Increased cell size variability of high variability subpopulations 
was maintained after passage in culture and regardless of seeding density 
(Figures 3.10, 3.11). Taken together, these high variability clonal 
subpopulations display an enhanced and heritable ability to generate 
diversity across multiple phenotypic dimensions.  
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Figure 3.8: High variability subpopulations exhibit three-dimensional 
size variability  
The first principal component of 3D size coefficient of variation was used 
to assess three-dimensional size variability from indicated MDA-MB-231-
derived (a) and CN34-derived (b) subpopulations. Error bars indicate 
s.e.m. of three independent experiments. P-values were derived using 
two-sided t-test. 
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Figure 3.9: High variability subpopulations exhibit no significant 
difference in cell cycle phasing 
Fixed cells from indicated MDA-MB-231-derived (a) and CN34-derived 
(b) subpopulations were stained with DAPI and analyzed by flow 
cytometry to measure DNA content. Histograms of each population are 
shown (left). Watson pragmatic cell cycle analysis was performed in 
FlowJo to assess cell cycle phasing (right). 
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Figure 3.10: High variability subpopulations maintain relative size 
variability after passage in culture 
Subpopulations from indicated MDA-MB-231-derived (a) and CN34-
derived (b) subpopulations were passaged five times in culture under 
standard cell culture conditions and then imaged and analyzed for cell 
size coefficient of variation. 
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Figure 3.11: High variability subpopulations exhibit increased cell size 
variability at different seeding densities 
Indicated MDA-MB-231-derived (a) and CN34-derived (b) subpopulations 
were seeded at various densities and then imaged and analyzed for cell 
size coefficient of variation. 
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3.3 High variability subpopulations exhibit metastatic fitness 
Systemic metastasis 
Metastatic colonization of an end organ represents a major 
bottleneck during cancer evolution that would greatly benefit from 
diversity generation and is clinically responsible for the majority of cancer 
deaths (Aktipis et al., 2013; Gupta and Massague, 2006; Klein, 2013). The 
identification of subpopulations with high versus low diversification 
potential from the same individual patients’ cancer populations allowed 
for testing the impact of intra-clonal diversification capacity on metastatic 
colonization. Because diversity generation should broadly enhance cancer 
evolution, in the context of the metastasis, diversity is likely to benefit 
colonization of multiple organs by increasing the likelihood of successful 
metastasis. To assess broad colonization capacity, cells were inoculated 
into arterial circulation of mice by intracardiac injection, which allows 
cells to arrest in the capillary beds of numerous organs. High variability 
subpopulations exhibited enhanced systemic metastatic capacity as 
determined by total tumor burden (Figure 3.12).  Additionally, this 
increased tumor burden was in large part attributed to an increased 
number of systemic metastatic foci (Figure 3.13), indicating an increased 
frequency to colonize systemic sites as opposed to an increased growth 
rate of the formed metastases.  
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Figure 3.12: High variability subpopulations exhibit enhanced systemic 
metastatic capacity 
Bioluminescence quantification of total body metastatic burden by 4x104 
MDA-derived cell populations after 42 days (a) and 2x105 CN-derived cell 
populations after 72 days (b) following inoculation into arterial circulation 
via intracardiac injection. P-values were derived using two-sample (a) and 
one-sample (b) one-sided t-test; n=5-6. Representative mouse and organ 
bioluminescence are shown. 
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Figure 3.13: High variability subpopulations exhibit increased systemic 
colonization frequency 
Systemic metastatic foci per mice were counted as distinct, minimal 
bioluminescence signals cells from indicated MDA-MB-231-derived (a) 
and CN34-derived (b) subpopulations. P-values were derived using two-
sample (a) and one-sample (b) one-sided t-test.   
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Organ metastasis 
 To confirm the increased colonization capacity of high variability 
subpopulations in a more clinically relevant context, these populations 
were assessed for the capacity to colonize the lung and liver, two of the 
most common sites of breast cancer metastasis (Siegel et al., 2015). High 
variability subpopulations derived from both human lines more efficiently 
colonized the lung upon tail vein injection (Figure 3.14) and the liver upon 
portal circulation injection (Figure 3.15), indicating that the enhanced 
metastatic capacity is broadly applicable to multiple organs posing 
diverse selective barriers. Additionally, to confirm that high variability 
populations contribute to metastasis to a greater degree in a mixed 
population with numerous subclones, a mixed population consisting of an 
equal number of high and low variability cells labeled with barcodes was 
generated. Portal circulation inoculation of this mixed population 
revealed high variability cells to contribute between 81.2% to 99.6% of 
formed liver metastases as measured by quantitative PCR of DNA 
barcodes (Figure 3.16), demonstrating that high variability cells 
maintained an increased metastatic capacity in a mixed population. The 
ability of high variability subpopulations to both generate phenotypic 
diversity and metastasize more efficiently is consistent with a positive role 
for phenotypic diversification in cancer progression. 
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Figure 3.14: High variability subpopulations exhibit increased lung 
colonization capacity 
Bioluminescence quantification of lung metastases by 4x104 MDA-derived 
cell populations after 70 days (a) and 2x105 CN-derived cell populations 
after 112 days (b) following inoculation into the tail vein. P-values were 
derived using one-sided Mann Whitney U test; n=5. Representative 
bioluminescence and lung histology is shown. 
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Figure 3.15: High variability subpopulations exhibit increased liver 
colonization capacity 
Ex vivo bioluminescence quantification of liver metastases by 4x104 MDA-
derived cell populations after 39 days (a) and 2x105 CN-derived cell 
populations after 91 days (b) following inoculation into the portal 
circulation. P-values were derived using one-sided Mann Whitney U test; 
n= 5. Representative bioluminescence and gross histology are shown. 
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Figure 3.16: High variability subpopulations exhibit increased liver 
colonization capacity in a mixed population  
5x105 cells consisting of equal parts of HV-M42 cells, labeled with 
blasticidin resistance gene, and LV-M100 cells, labeled with puromycin 
resistance gene, were inoculated into the portal circulation. Liver 
metastases were extracted after 28 days and processed for quantitative 
PCR measurement of genomic DNA resistance genes. 
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Clinical metastasis 
 In order to corroborate the role of phenotypic diversification in 
metastatic progression, the next goal was to determine whether 
phenotypic diversity was associated with clinical outcomes. Given the 
observation of increased nuclear size variability in high variability 
subpopulations (Figure 3.17) as well as the ability to distinctly label nuclei 
with DNA stains, this tractably quantifiable parameter of nuclear size was 
used as a readout of phenotypic variability in human invasive breast 
cancer tumor core biopsies. A tissue microarray containing 168 useable 
core biopsies of primary breast cancer tumors was stained with DAPI to 
label nuclei, imaged by confocal microscopy, and analyzed by automated 
image analysis to measure cancer cell nuclei sizes within each core. 
Consistent with the findings in the clonal populations, nuclear area 
variability of cancer cells was significantly increased in tumors of patients 
with more advanced stage disease (Figure 3.18). Primary tumors that 
progressed to lymph nodes displayed significantly higher variation in 
nuclear area than lymph node negative tumors. Furthermore, primary 
tumors that progressed to distant metastases exhibited significantly higher 
nuclear area variation than those tumors that did not metastasize. Mean 
nuclear size and mitotic index did not significantly correlate with disease 
stage (Figure 3.19). These clinical correlations are consistent with our 
findings that cancer populations with greater diversification potential 
positively contribute to metastatic disease.  
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Figure 3.17: High variability subpopulations exhibit increased nuclear 
area variability 
Nuclear area variability as measured by automated image analysis of 
indicated MDA-MB-231-derived (a) and CN34-derived (b) 
subpopulations.   
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Figure 3.18: Nuclear area variability associates with human breast cancer 
metastasis 
(a) NCI CDP Breast Cancer Progression Tissue Microarray was stained 
with DAPI, imaged by confocal microscopy, and analyzed for nuclear area 
coefficient of variation for each breast cancer core. P-values were derived 
using one-sided t-test. (b) Representative images with measured cancer 
cell nuclei (yellow boundary) are shown; scale bar = 50um. 
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Figure 3.19: Nuclear area variability in human breast cancer is not 
dependent on mean nuclear area or mitotic index 
NCI CDP Breast Cancer Progression Tissue Microarray was stained with 
DAPI, imaged by confocal microscopy, and analyzed for mean nuclear 
area (a) and mitotic index (b) in each breast cancer core. P-values were 
derived using one-sided t-test.  
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3.4 Molecular characterization of high variability subpopulations 
Genomic analysis 
These clonal subpopulations of cells derived from isogenic 
backgrounds offered the potential for studies into the molecular basis of 
cancer variability. Given the contribution of genomic instability to tumor 
heterogeneity (de Bruin et al., 2014; Greaves and Maley, 2012), high 
variability subpopulations were assessed for mutational burden. Genomic 
DNA was isolated from subpopulations and processed for whole exome 
sequencing to allow for quantification of single-nucleotide variant and 
insertion-deletion mutation frequencies. The mutational profiles allowed 
for reconstruction of phylogenic relationships as subpopulations diverged 
from an ancestral parent population (Gerlinger et al., 2012). Exome 
sequencing revealed that high variability subpopulations diverged from a 
common high variability ancestor and exhibited genetic similarity to the 
parental MDA-MB-231 population (Figure 3.20), indicating that 
substantial genetic mutational changes did not accumulate as these 
subpopulations clonally expanded. Furthermore, high variability 
subpopulations did not differ in the number of population-specific nucleic 
acid variants relative to low variability subpopulations or the parental 
population (Figure 3.20). While it is difficult to exclude the contribution of 
nucleic acid mutations to subpopulation heterogeneity, the comparable 
genetic phenotypes and relative genetic stability in the isogenic high 
variability subpopulations suggests that enhanced genetic diversification 
may not be the primary source of the observed phenotypic diversity. 
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Figure 3.20: No evidence of genomic instability as a factor associated 
with high variability subpopulations 
(a) Phylogenic tree based on genomic variant allele frequencies as 
measured by exome sequencing from cell populations. Genetic distance of 
subpopulations relative to MDA-MB-231 parent cell line (b) or from 
inferred HV or LV common ancestor (c) as determined by Nei’s genetic 
distance. (d) Variants found only in the indicated subpopulations at any 
frequency greater than zero were counted.   
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Transcriptomic variability 
 In order to identify additional molecular mechanisms that could 
contribute to phenotypic diversity, single-cell RNA-sequencing from high 
and low variability subpopulations was performed to assess gene 
expression variability between cells (Figure 3.21), which could contribute 
to the functional variability between cells in high variability 
subpopulations. Cells were sorted by flow cytometry into individual wells 
with lysis buffer to expose RNA for immediate generation of barcoded 
cDNA. Barcoded cDNA was then pooled and processed for generation of 
sequencing libraries. 
 
 
 
 
Figure 3.21: Single-cell RNA-sequencing to compare cell-to-cell gene 
expression variability 
Schematic for single-cell RNA sequencing and transcriptomic variability 
analysis. 
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 Assessment of single-cell RNA sequencing quality and fidelity 
demonstrated appropriate spike-in expression and no difference in spike-
in variability between wells (Figure 3.22). Total transcript abundance per 
cell showed no significant differences between high and low variability 
subpopulations (Figure 3.23). Moreover, global mean transcript 
abundance was also not significantly different between high and low 
variability subpopulations (P = 0.91 for HV-C57 vs LV-C92 & P = 0.62 for 
HV-M42 vs LV-M26 by two-sided paired t-tests).  
 
 
 
 
 
Figure 3.22: Spike-in expression and variability in single cell wells 
indicates appropriate single-cell sequencing fidelity  
(a) Mean expression of spike-in transcripts per well as assessed by single 
cell sequencing was plotted against known spike-in concentrations. (b) 
Coefficient of variation of spike-in transcripts between wells containing 
the indicated population of cells was calculated. P-values were derived 
using two-sided paired t-test.  
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Figure 3.23: Single-cell total transcripts was similar between high and 
low variability cells 
Relative transcript abundance per cell from indicated MDA-derived 
subpopulations (a) and CN-derived subpopulations (b). 
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 Interestingly, linear and nonlinear clustering (Amir el et al., 2013) 
of single-cell transcript expression profiles could not classify high or low 
variability subpopulations (Fig. 3.24), suggesting that averaged over-
expression or repression of a gene or gene set may not be the primary 
cause of phenotypic variation recurrently observed in high variability 
subpopulations (Altschuler and Wu, 2010). However, global cell-to-cell 
transcript expression variability, as assessed by quantification of 8,218 
transcripts from single MDA-MB-231-derived high variability cells, was 
significantly elevated relative to expression variability between single low 
variability cells (53.9% transcripts with higher CV in HV-M42; P = 7e-8 by 
two-sided paired t-test; Figure 2.25). The same was observed for single 
cells from the HV-C57 subpopulation (5,826 transcripts; 55.0% transcripts 
with higher CV in HV-C57; P = 3e-10 by two-sided paired t-test; Figure 
3.25).  
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Figure 3.24: Gene expression profiles of cells from high and low 
variability subpopulations are similar 
(a) Principal component analysis was performed on single-cell transcript 
expression profiles from MDA-derived subpopulations (left) and CN-
derived subpopulations (right). (b) Visualization of transcript expression 
profiles of 10 cells from selected MDA-derived subpopulations (left) and 
12 cells from selected CN-derived subpopulations using t-distributed 
stochastic neighbor embedding (t-SNE). 
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Figure 3.25: High variability populations exhibit increased cell-to-cell 
transcript expression variability 
Transcriptomic variability analysis was performed by calculating 
expression coefficient of variation for each transcript between cells from 
MDA-derived subpopulations (a; n=10 single cells per population) and 
from CN-derived subpopulations (b; n=12 single cells per population). 
Mean transcript coefficient of variation was calculated for all transcripts. 
P-value was derived from two-sided paired t-test. Percentages of 
transcripts with higher CV in each population are shown. Representative 
high variability transcripts in single cells are shown (right); n=10 single 
cells for MDA-derived populations and n=12 single cells for CN-derived 
populations.   
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Characterization of transcriptomic variability 
To assess the robustness of this molecular phenotype, sampling 
analyses of the single-cell sequencing experiments were performed. While 
more abundant transcripts are known to be detected with higher accuracy, 
elevated transcriptomic variability was observed regardless of transcript 
abundance (Figure 3.26). To determine whether sequencing from limited 
number of cells affected the outcome, random sampling of single cells 
from subpopulations was performed to determine if the enhanced 
transcriptomic variability could be detected with fewer cells. Indeed, 
transcriptomic variability was observed when setting the analysis to as 
few as five cells per population (Figure 3.27). Additionally, to determine if 
a unique cell was responsible for the molecular variability, sampling was 
performed to assess population transcriptomic variability following 
removal of each single high variability cell sequenced. Transcriptomic 
variability was consistently detected regardless of which high variability 
cell was excluded from the analysis (Figure 3.28), indicative of robust and 
indiscriminate population-level variability. While the increased 
transcriptomic variability appears modest, this effect is consistently 
observed under different analysis parameters and in two subpopulations 
derived from independent breast cancer populations. Taken together, 
these findings indicate that phenotypically diverse, metastatic cancer 
subpopulations maintain enhanced intra-clonal transcriptomic variability 
generation capacity. 
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Figure 3.26: Increased cell-to-cell transcript expression variability is not 
dependent on transcript abundance 
Log-ratios of transcript CV mean were calculated by using varying 
number of transcripts, ordered by descending mean single cell expression. 
Analysis was performed using a minimum of 100 transcripts. All cells, 10 
for each MDA-derived HV and LV subpopulation (a) and 12 for each CN-
derived HV and LV subpopulation (b), were used for analysis. 
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Figure 3.27: Increased cell-to-cell transcript expression variability is 
detected with as few as five cells per population 
Log-ratios of transcript CV mean were calculated by sampling MDA-
derived (a) and CN-derived (b) HV or LV subpopulations 10 times using 
different set sizes and calculating the mean transcript CV for HV and LV 
subpopulations. P-values were derived using one-sided paired t-test. All 
transcripts were used for analysis. Significant p-values are in red. Color 
scales are shown. 
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Figure 3.28: Increased cell-to-cell transcript expression variability is 
detected regardless of which cell is excluded from analysis 
Cumulative frequency distribution is shown from sampling analysis. (a) 
All possible combinations of six cells were sampled from the 10 MDA-
derived HV cells with one specific cell removed (set size of 9) and 
distribution of mean CV is plotted (blue, 10 possible combinations to 
exclude each of the 10 cells). (b) All possible combinations of six cells were 
sampled from the 12 CN-derived HV cells with one specific cell removed 
(set size of 11) and distribution of mean CV is plotted (blue, 12 possible 
combinations to exclude each of the 12 cells).  Distributions of mean CV 
from samplings of six cells from all HV cells (red, 1 possible combination 
to include all cells) and all LV cells (grey, 1 possible combination to 
include all cells) are shown.   
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Transmission of variability to protein expression 
 To validate the relevance of transcriptomic variability as it pertains 
to biological function, flow cytometry was used to assess protein-level 
variation. XPNPEP3 and UPF2, two genes that displayed high transcript-
level variability in both high variability subpopulations (Table 3.1) and 
whose protein expression per cell could be readily quantified in a high-
throughput manner by flow cytometry, demonstrated a consistent level of 
increased protein expression variability in high variability subpopulations 
(Figure 3.29). These findings were extended to the following additional 
five proteins that could be readily quantified by flow cytometry: ALDOA, 
PABPC1, HNRNPA1, CD110, and HNRNPA0. In all high and low 
variability subpopulations, we observed a significant correlation between 
transcript-level variation and protein-level variation for the seven genes 
tested (Figure 3.30) with no consistent correlation in mean protein 
abundance (Figure 3.31). These findings reveal that transcript variation is 
transmitted to the protein level and highlight molecular variability as a 
principal feature of high variability subpopulations.  
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Table 3.1: Top 20 most variable genes in common to MDA-derived and 
CN-derived high variability subpopulations 
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Figure 3.29: Cell-to-cell transcript expression variability is transmitted to 
the protein-level 
Flow cytometry was used to assess UPF2 (a) and XPNPEP3 (b) protein 
coefficient of variation in subpopulations by assaying over 2.5x104 cells. P-
values were derived using two-sample (MDA) or one-sample (CN) one-
sided t-test. 
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Figure 3.30: Cell-to-cell transcript expression variability is correlated 
with protein expression variability 
Protein CV log-ratios of seven proteins as measured by flow cytometry 
from MDA-derived (a) and CN-derived (b) subpopulations was compared 
to transcript CV log-ratios measured by single-cell RNA sequencing. P-
value was derived from testing Pearson’s correlation coefficient with one-
side. 
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Figure 3.31: Mean transcript expression is not consistently correlated 
with mean protein expression 
Protein mean expression log-ratios as measured by flow cytometry from 
MDA-derived (a) or CN-derived (b) was compared to transcript mean 
expression log-ratios as measured by single cell RNA sequencing. 
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3.5 Spliceosome-related gene transcripts are high variability 
Validation of spliceosome-related gene variability 
The next goal was to identify a potential mechanism that could 
contribute to transcriptomic variation in high variability subpopulations. 
MDA-derived and CN-derived subpopulations displayed similarity in 
high variability genes (Table 2.1), many of which alone could contribute to 
global transcriptomic variability such as chromatin modifiers (SENP7, 
ARID1A), transcription factors (TCF7L2, SP3), and regulators of nonsense-
mediated decay (UPF2). While individual genes are likely to contribute to 
the effect seen in high variability populations, any coordinated variation 
of a common subset of transcripts may reveal a major contribution to cell-
to-cell variability. To identify regulatory networks that might be 
responsible for transcriptomic variation, variable transcripts were 
searched for functional gene sets that might contribute to molecular 
variability. Transcripts were binned into four categories depending on 
whether relative transcript variability was increased in either or both 
MDA-derived and CN-derived high variability subpopulations. Pathway 
discovery analysis using iPAGE (Goodarzi et al., 2009) revealed 
spliceosome machinery and myeloid cell differentiation gene transcripts 
as the only two gene sets to exhibit higher expression variability in high 
variability subpopulations derived from both patients’ cancer populations 
(Figure 3.32). This raised the possibility that cell-to-cell variation in the 
expression levels of splicing genes and the resultant mRNA processing 
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activity may represent a conceivable mechanism through which 
population-level heterogeneity of mature transcripts may be achieved at a 
global scale (Munsky et al., 2012).  
 
 
 
 
 
Figure 3.32: Pathway analysis reveals spliceosome machinery and 
myeloid cell differentiation gene transcripts as gene sets with variable 
expression 
Pathway analysis was used to identify gene sets that are enriched in 
transcripts with high expression variability in either or both HV 
subpopulations. Enrichment scale is shown below. 
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Intron retention variability 
 Intron retention, a product of improper splicing, is known to lead 
to transcript degradation via non-sense mediated decay (Wong et al., 
2013). Increased intron retention could thus reduce the expression of a 
large number of mature transcripts. Given the expression variation of 
spliceosome machinery components, variation in constitutive spliceosome 
activity in HV cells could cause enhanced variation in global intron 
retention.  Variation in intron retention could then contribute to transcript 
abundance variation. Indeed, high variability subpopulations 
demonstrated higher cell-to-cell intron retention variation, as determined 
by analysis of 1,132 matched introns from MDA-derived cells (54.8% 
retained introns with higher CV in HV-M42, P = 1e-4 by one-sided paired 
t-test; Figure 2.33) and 1,666 matched introns from CN-derived cells 
(57.6% retained introns with higher CV in HV-C57, P = 2e-11 by one-sided 
paired t-test; Figure 3.33). 
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Figure 3.33: Intron retention variability is observed in high variability 
subpopulations 
Intron retention (IR) variability analysis was performed by calculating 
expression coefficient of variation for each IR measurement between cells 
from MDA-derived (a) and CN-derived (b) subpopulations. Mean IR 
coefficient of variation was calculated. P-value was derived from one-
sided paired t-test. Percentages of retained introns with higher CV in each 
population are shown. Representative high variability retained intron 
expression in single cells is shown (right); n=10 single cells for MDA-
derived populations and n=12 single cells for CN-derived populations.  
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Exon-exon junction variability 
 Additionally, if this intron retention variation is propagated, 
variation should be apparent in further processed forms of pre-mRNA. 
Indeed, exon-exon junction expression variability measured from single 
cell sequencing experiments was significantly increased in high variability 
subpopulations from MDA-derived cells (54.7% exon-exon junctions with 
higher CV in HV-M42, P = 2e-4 by one-sided paired t-test; Figure 3.34) 
and CN-derived cells (65.3% exon-exon junctions with higher CV in HV-
C57, P = 8e-10 by one-sided paired t-test; Figure 3.34). This molecular 
variability could be caused by variation in splicing as well as varied decay 
of improperly spliced transcripts. Consistent with our findings, intron 
retention has been previously observed to be the most significant splicing 
alteration in breast cancer patient samples (Eswaran et al., 2013). These 
findings reveal enhanced splicing and intron-retention variability as one 
feature of high variability subpopulations. 
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Figure 3.34: Exon-exon junction variability is observed in high 
variability subpopulations 
Exon-exon junction transcript variability analysis was performed by 
calculating expression coefficient of variation for each exon-exon junction 
transcript between cells from MDA-derived (a) and CN-derived (b) 
subpopulations. Mean exon-exon junction transcript coefficient of 
variation was calculated. P-value was derived from one-sided paired t-
test. Percentages of exon-exon junction transcripts with higher CV in each 
population are shown. Representative high variability exon-exon junction 
transcript expression in single cells is shown (right); n=10 single cells for 
MDA-derived populations and n=12 single cells for CN-derived 
populations.  
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3.6 Variable cell-to-cell expression of SNRNP40 increases metastatic colonization  
 
Engineered variation of SNRNP40 increases metastatic colonization 
 To determine if spliceosomal gene variability contributed to 
increased metastatic colonization, the next goal was to assess whether 
enforced modulation of a high variability spliceosomal gene could 
recapitulate the metastatic capacity seen in high variability 
subpopulations. While high variability subpopulations display variability 
in many spliceosomal genes, focused study on a single spliceosomal gene 
could serve as a model by which other spliceosomal genes function, but 
may recapitulate only a fraction of the effects seen in high variability 
subpopulations. Focused study was performed on SNRNP40, a 
component of the U5 snRNP complex, because this gene exhibited high 
transcript variability in high variability subpopulations from single-cell 
sequencing experiments (Figure 3.35), was among the top 3 most variable 
spliceosomal gene transcripts from single-cell sequencing experiments 
(Table 3.2), and whose protein expression could be readily quantified by 
immunofluorescence-based imaging on confocal microscopy. Indeed, high 
variability subpopulations displayed increased protein-level variability of 
SNRNP40 (Figure 3.36).  
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Figure 3.35: SNRNP40 transcript (NM_004814) is variable in high 
variability subpopulations 
Single cell expression of SNRNP40 transcript (NM_004814) from MDA-
derived (a) and CN-derived (b) subpopulations. P-value to test variation 
was performed using Levene’s test.  
 
 
 
 
Table 3.2: Top 5 most variable spliceosomal genes in common to MDA-
derived and CN-derived high variability subpopulations 
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Figure 3.36: Variable cell-to-cell expression of SNRNP40 protein in high 
variability subpopulations 
Subpopulations were quantified for SNRNP40 protein levels by 
fluorescence confocal microscopy (a) and analyzed for protein expression 
coefficient of variation (b). P-values were derived from two-sample 
(MDA) or one-sample (CN) one-sided t-test. 
 
 
 To determine whether population-level variation in SNRNP40 
observed with high variability cells was sufficient to enforce metastatic 
fitness, a low variability subpopulation was used to enforce modulation of 
SNRNP40 expression. Populations of LV-M100 cells were individually 
transduced with SNRNP40 over-expression constructs and shRNAs 
targeting SNRNP40 at various titers to generate populations with varying 
levels of SNRNP40 (Figure 3.37a). These populations were pooled to 
generate a mixed population with increased cell-to-cell SNRNP40 
expression variability without significantly altering mean SNRNP40 
expression (Figure 3.37b; mean: Control = 9.0, hiCV=8.9, P = 0.19 by two-
sided t-test; CV: Control = 0.068, hiCV= 0.104, P = 7e-14 by Levene’s test). 
Functional testing of this population in metastasis revealed that increased 
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cell-to-cell variability in SNRNP40 expression enhanced the ability of 
these cells to metastasize more efficiently and colonize more sites 
systemically (Figure 3.37), suggesting that variation in SNRNP40 between 
cells could, in part, contribute to enhanced metastatic capacity observed in 
high variability subpopulations. Next, SNRNP40 over-expression and 
depletion cell lines were tested individually to determine whether the cells 
with increased or decreased SNRNP40 expression imparted the enhanced 
fitness to the pooled population. While increased SNRNP40 expression 
did not affect metastatic capacity, SNRNP40 depletion promoted systemic 
metastatic colonization (Figure 3.38). 
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Figure 3.37: Engineered variation of SNRNP40 increases metastatic 
colonization 
(a) Populations of LV-M100 cells were generated with over-expression of 
SNRNP40, shRNA-mediated knockdown of SNRNP40, empty vector, or 
control shRNA vector at varying titers to generate various population-
level expression of SNRNP40 as measured by qRT-PCR. (b) Populations 
generated in (a) were pooled to generate a high SNRNP40 expression 
variability LV-M100 population and were assayed for protein expression 
by fluorescence microscopy. (c) 105 cells from pooled LV-M100 
populations were inoculated via intracardiac injection and monitored by 
bioluminescence flux. Representative mice are shown. P-value was 
derived from one-sided t-test; n = 6. (d) Systemic metastatic foci per mice 
were counted as distinct, minimal bioluminescence signals. P-value was 
derived using one-sided t-test. 
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Figure 3.38: SNRNP40 depletion, not over-expression, promotes 
metastatic colonization
(a) 105 LV-M100 cells with SNRNP40 over-expression were inoculated by 
intracardiac injection and monitored by bioluminescence; n=5. (b) 105 LV-
M100 cells with SNRNP40 depletion were inoculated by intracardiac 
injection and monitored by bioluminescence. Representative mice are 
shown; n=5. (c) Systemic metastatic foci per mice were counted. P-values 
were derived from one-sided t-test. 
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SNRNP40 regulates genes found to be variable in high variability subpopulations 
and is required for proper intron exclusion 
The next goal was to determine whether SNRNP40 contributed to 
the gene expression variability seen in high variability subpopulations. 
The working model was that variable levels of SNRNP40 allows for 
transmission of variability to many transcripts dependent on SNRNP40 
expression. Thus, siRNA-mediated depletion of SNRNP40 followed by 
RNA-sequencing was performed to identify these dependent transcripts 
with high magnitude of expression change indicative of strong 
transmission. If variable expression of SNRNP40 contributes to gene 
expression variability seen in high variability subpopulations, SNRNP40-
dependent transcripts would be enriched among variable transcripts in 
high variability subpopulations. Indeed, transcripts with high magnitude 
expression change in SNRNP40 knockdown cells were enriched among 
variable transcripts between high variability single cells (Figure 3.39a). 
Additionally, absolute log-fold expression change significantly correlated 
with single-cell transcript variability ratios (Figure 3.39b).  These findings 
suggest that SNRNP40 contributes in part to the expression of a set of 
variable transcripts in breast cancer cells. Additionally, SNRNP40 
depletion led to an increase in intron retention (Figure 3.40), consistent 
with intron retention variability observed in high variability 
subpopulations, although the modest effect may be attributed to 
perturbation of only a single spliceosomal gene. 
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Figure 3.39: SNRNP40 regulates gene expression consistent with gene 
expression variability seen in highly variable subpopulations. 
LV-M100 cells were transfected with two siRNAs targeting SNRNP40 and 
processed for gene expression analysis. (a) Absolute log-fold change was 
calculated to determine the magnitude of change. High magnitude change 
was defined as absolute log-fold change > 1. Highly variable transcripts 
were defined using single-cell RNA-sequencing experiments as log2(HV-
M42/LV-M26 transcript CV ratio) > 1.5. The calculated mutual 
information value (in bits) and z-score are provided. P-value was derived 
using two-sided Fisher’s exact test. Also shown are the enrichment scores, 
presented as logP (positive for enrichments and negative for depletions), 
where P is calculated from hypergeometric distribution (shown as a 
heatmap with blue and gold showing depletion and enrichment, 
respectively). (b) Gene expression variability ratios of 6,906 transcripts 
derived from single-cell RNA-sequencing were binned into 100 bins. For 
transcripts in each bin, the absolute log-fold expression change of 
SNRNP40 siRNA treatment relative to control siRNAs was calculated, 
averaged, and plotted. Robust linear regression is shown in black. Two-
sided spearman’s correlation and corresponding p-value are shown. 
 
 
 
 146 
 
Figure 3.40: SNRNP40 promotes proper intron exclusion 
Log-fold intron retention ratio was calculated for each transcript and 
plotted as a histogram. Dashed red line indicates mean. Percentages of 
intron retention ratios above and below zero are shown. P-value was 
derived from two-sided t-test of log-ratio as compared to zero. 
 
 
Low SNRNP40 is associated with metastasis in human breast cancer 
 Given the experimental role of SNRNP40 in metastasis, human 
breast cancer samples were assessed for SNRNP40 expression to 
determine if this gene was associated with clinical outcomes. Indeed, 
decreased SNRNP40 transcript-level expression in bulk primary breast 
cancer sampled was associated with increased metastatic relapse 
outcomes in multiple independent datasets (Figure 3.41). Furthermore, 
low SNRNP40 copy number correlated with worse overall survival 
(Figure 3.41). These findings provide clinical association support for 
SNRNP40 expression in human breast cancer progression. While tumors 
can achieve reduced SNRNP40 expression through mean expression or 
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copy number changes, our experimental model suggests that cancer 
subpopulations may achieve SNRNP40 silencing through deregulation in 
a subset of cells that is not easily observed using averaged measurements.  
Figure 3.41: Low SNRNP40 expression is associated with metastasic 
outcomes in human breast cancer 
Kaplan-Meier curves of distant metastasis-free survival (DMFS) from 
GSE33926 (Kuo et al., 2012) (a), GSE2034 (Wang et al., 2005) (b) and 
kmplotter meta-analysis (Gyorffy et al., 2010) (c) as a function of primary 
tumor SNRNP40 expression in breast cancer. (d) Kaplan-Meier curve of 
overall survival from TCGA samples based on SNRNP40 copy number 
(Cancer Genome Atlas, 2012). P-values were derived from log-rank test. 
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3.7 Discussion 
Cell-to-cell gene expression variability  
 Gene expression variability in cell populations can be driven by a 
combination of stochastic and deterministic processes (Hanna et al., 2010). 
While stochastic changes can impact population fitness, deterministic 
processes can more reliably benefit evolution over multiple generations. 
Single-cell transcriptomic analyses have revealed deterministic molecular 
programs that regulate gene expression heterogeneity in induced 
pluripotent stem cell differentiation and immune cells responses 
(Buganim et al., 2012; Shalek et al., 2013). In cancer, analysis of gene 
expression cell-to-cell variability has been limited though has mainly 
pertained to stem-like characteristics of individual cells within 
glioblastoma tumors (Patel et al., 2014). The work presented here 
illustrates another regulatory program involved in cell-to-cell gene 
expression variability, namely variable splicesomal gene expression 
between cells as a catalyst for gene expression variability. 
 
Splicing as regulator of global gene expression networks 
 While constitutive splicing serves a necessary processing function 
to generate protein-coding transcripts from genomic sequences, minimal 
deregulation of splicing factors has the potential for amplified alterations 
of gene regulatory networks and gene expression states. Key splicing 
factors are understood to be required for maintenance of robust 
transcriptomes as feedback loops exist to maintain steady-state levels and 
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direct molecular programs (Jangi and Sharp, 2014). Furthermore, bone-
marrow-derived dendritic cell populations in response to 
lipopolysaccharide display variability in splice isoforms between cells 
(Shalek et al., 2013). Consistent with the findings presented here, 
heterogeneous transcriptional signatures and splice isoform variation 
have been observed in glioblastoma (Patel et al., 2014) and likely 
contribute to cancer progression. Additionally, intron retention has been 
observed to regulate the expression of genes involved in nuclear shape as 
well as splicing factor genes (Wong et al., 2013), indicating a complex 
regulatory network as well as phenotypic consequences associated with 
perturbed splicing.  
 
Upstream source of molecular variability 
 While spliceosome gene expression variability has the potential to 
contribute in part to the observed transcriptomic and phenotypic 
variability in high variability subpopulations, the upstream cause of this 
transcript-level variability remains unknown. One approach to 
characterize the source is to determine whether the observed variability is 
due to dynamic variability within a single cell, namely high fluctuations in 
gene expression over time, or stable variation between cells, namely 
certain cells always express low levels while other cells always express 
high levels. Dynamic variability within cells would suggest that molecular 
instability at the level of transcription or stability mediate transcript-level 
variability, whereas stable variation between cells would suggest unequal 
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cell divisions might be responsible. This question can be addressed by 
using a fluorescent reporter of endogenous transcripts that display high 
variability and performing live cell imaging to visualize protein 
expression levels between cells and over time.  
 Given the maintained genomic integrity in these populations, 
epigenetic alterations are a likely candidate for the source of variability. 
Histone modifications and methylation of CpG islands are known to 
contribute to cancer progression and have known roles in affecting 
robustness of transcriptional activity (Rodriguez-Paredes and Esteller, 
2011). Future experiments include analysis of transcriptional activity of 
variable genes as well as analysis of DNA methylation in single cells 
within highly variable subpopulations. Furthermore, if epigenetic 
alterations are contributing to phenotypic and molecular variability, the 
use of epigenetic drugs has the potential to suppress variability and slow 
cancer evolution.  
 Additionally, the class of genes known as phenotypic capacitors 
have the potential to contribute to transcript-level variability. Phenotypic 
capacitors function to buffer noise and maintain phenotypic robustness; 
thus, upon failure of a capacitor under external pressures, systems lose 
robustness and result in greater phenotypic variability. The first capacitor 
described was Hsp90, whose decreased expression resulted in uncovering 
of genetically-encoded morphological variation as well as developmental 
plasticity (Queitsch et al., 2002; Rutherford and Lindquist, 1998). To assess 
whether capacitors could contribute to variability observed in breast 
cancer populations, loss-of-function screens could be performed to 
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identify capacitors that regulate phenotypes and molecular functions 
identified in highly variable subpopulations. These screens have 
previously been performed in yeast and have identified chromatin 
remodeling complexes as capacitors (Levy and Siegal, 2008), supporting 
the notion of epigenetic alterations as a potential contributor to cell-to-cell 
variability.  
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3.7 Materials and Methods 
Cell culture 
MDA-MB-231, CN34, and derived sub-population cells were propagated 
as previously described (Tavazoie et al., 2008). MDA-MB-231 cells and 
their derivatives were maintained in DMEM supplemented with 10% FBS, 
glutamine, pyruvate, penicillin, streptomycin and Fungizone. CN34 cells 
and their derivatives were maintained in M199 supplemented with 2.5% 
FBS, 10 !g ml−1insulin, 0.5 !g ml−1 hydrocortisone, 20 ng ml−1 EGF, 100 ng 
ml−1 cholera toxin, glutamine, pyruvate, penicillin, streptomycin and 
Fungizone. Cells in culture were routinely tested for mycoplasma 
contamination. Clonal populations were generated by seeding cells 
sparsely, picking individual colonies using cloning discs (Sigma), and 
expanding the populations to approximately 105 cells when cells were 
seeded to be imaged for size measurements. 
Cell size measurements and coefficient of variation analysis 
3x104 cells were seeded on coverslips and stained with HCS CellMask Red 
(Invitrogen) and DAPI. Numerous fields were imaged on DeltaVision 
Image Restoration Microscope to capture at least 100 cells per population. 
Cell size parameters were measured using Cell Profiler 2.0. Debris was 
filtered out by generating a histogram of (cytoplasmic area – nuclear area) 
and applying a minimum threshold in R. To calculate coefficient of 
variation (standard deviation / mean) for each clonal population, a 
sampling size was determined from the clonal population with the fewest 
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cells analyzed (96 cells in the MDA-MB-231 population and 206 cells in the 
CN34 population). Subpopulations with more cells imaged than the 
sampling size were sampled 100 times, with the average CV used in the 
final analysis. For each subpopulation, coefficient of variation was 
calculated for each size parameter, which includes cell area, cytoplasmic 
area, nucleus, perimeter, major axis length, and minor axis length. 
Principal component analysis was performed using all subpopulations on 
the coefficient of variations for all morphological parameters. The first 
principal component accounted for 93% and 91% of the variance in MDA 
and CN34 cell lines, respectively, and is used for all size variation 
analyses. 
 
Three-dimensional size coefficient of variation analysis 
Cells were fixed in 8% paraformaldehyde, permeabilized with 0.1% 
Triton-X, and stained with HCS CellMask Red. Cells were analyzed by 
ImageStream-X (Amnis) to measure cell size, nuclear size, perimeter, 
major axis, and minor axis. Principal component analysis was performed, 
and the first principal component was used for analyses. 
 
Proliferation  & colony formation assays 
For bulk population proliferation assays, 5x103 cells were seeded in 
triplicate and assayed WST-1 reagent (Roche) 72 hours after seeding. For 
colony formation assays, 200 cells were seeded in 10cm plates in triplicate 
and were allowed to grow for 10 days (MDA-derived cells) or 20 days 
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(CN-derived cells). Plates were fixed in 6% glutaraldehyde with 0.5% 
crystal violet and scanned. Colony areas were measured using ImageJ. R 
was used to remove debris, equalize colony numbers with samplings as 
above, and calculate coefficient of variation. 
Animal studies 
Animal experiments were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at The 
Rockefeller University. For in vivo experiments with MDA-derived cell 
lines, populations were transduced with a retroviral construct expressing 
a luciferase reporter (Ponomarev et al., 2004). CN34 parental cell line was 
previously labeled with luciferase reporter. Athymic female mice were 
used for intracardiac injection. NOD-SCID female mice were used for tail 
vein injections with MDA-derived cells, while NOD-SCID gamma female 
mice were used for tail vein injections with CN-derived cells. For 
intracardiac injections, cells in PBS were injected into the left ventricle of 
mice in a volume of 100ul. For tail vein injections, cells in PBS were 
injected into the tail vein of mice in a volume of 100ul. Portal circulation 
injections were performed as described in chapter 2.8. For portal 
circulation injection of mixed population, LV-M100 cells were transduced 
with pLKO.1 puro (Addgene plasmid #8453), and HV-M42 cells were 
transduced with pLKO.1 blast (Addgene plasmid #26655). Cells were 
mixed at a 1:1 ratio immediately before injections. In vivo bioluminescence 
was performed as described in chapter 2.8. 
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Tissue microarray analysis 
NCI CDP Breast Cancer Progression Tissue Microarray slides were 
deparaffinized, rehydrated, and exposed to Heat Induced Epitope 
Retrieval at pH 6 (Vector Labs) in a pressure cooker for 4 minutes. Slides 
were stained with DAPI, and tumor cores were imaged on Leica TCS SP5 
system at 40x. Images were analyzed using CellProfiler 2.0 to identify and 
measure cancer cell nuclei by Otsu Adaptive thresholding. A minimum 
nuclei size threshold was applied to remove stromal cell nuclei. Image 
acquisition and analysis were blinded until measurements were 
completed for all tumor cores. Mitotic index was calculated as follows: # 
mitotic cells / total cells for each tumor core. 
 
Exome sequencing and analysis 
Genomic DNA was extracted using DNEasy kit (Qiagen). Libraries were 
prepared using Nextera Extended Exome sequencing kit, as per 
manufacturer’s instructions (Illumina), and paired-end sequenced on 
HiSeq 2500 (Illumina). The analysis pipeline for the exome-seq data was 
based on the GATK best practices. Reads were aligned to the human 
genome (build hg19). The paired-end reads were then fixed and filtered 
using Picard (v. 1.107; http://picard.sourceforge.net/). The duplicates 
were also removed in the same step. Using GATK (v. 2.5) (McKenna et al., 
2010), the reads were realigned and recalibrated. mpileup (samtools (Li et 
al., 2009)) was used to create an input for VarScan (v2.3.6) (Koboldt et al., 
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2012). In VarScan, mpileup2snp and mpileup2indel commands were used 
to identify variants across all exome-seq samples. To study population 
genetic divergence, the frequencies of all variants identified (148,234) were 
used to generate phylogenic tree by Nei’s genetic distance using neighbor-
joining method in the PHYLIP package.  
RNA-sequencing of bulk populations 
For bulk population RNA-sequencing, RNA was extracted using total 
RNA isolation kit (Norgen Biotek) with DNAse I treatment followed by 
Ribo-Zero Gold rRNA removal (Epicentre). Libraries were generated 
using ScriptSeq v2 RNA-seq Library Preparation Kit (Epicentre) and run 
on HiSeq 2500 (Illumina). For RNA-sequencing data analysis, the reads 
were trimmed to remove matches to linkers and low-quality bases 
(cutadapt v1.2.1). Tophat (v. 2.0.8)(Kim et al., 2013) was then used to map 
the reads to the human transcriptome (build hg19). Cufflinks and 
cuffmerge (v.2.0.2) were then used to calculate reads per kilo base per 
million (RPKM) and consolidated results across the samples. Finally, 
cuffdiff (v.2.0.2) was used to calculate log-fold changes and the associated 
statistics.  
Single cell RNA-sequencing 
Single cell isolation, cDNA synthesis, amplification, and processing for 
Illumina sequencing were performed as described in detail (Islam et al., 
2012). To describe the protocol briefly, single cells were sorted by 
fluorescence-activated cell sorting 
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into 96-well plates containing cell lysis buffer, a biotin-labeled oligo-dT 
primer for capturing poly-adenylated mRNA, and a template-switching 
barcoded oligonucleotide to label transcripts from each cell. This 
template-switching oligonucleotide is incorporated at the 5’ end of 
complementary DNA generated in the next step. Once cells were 
captured, Superscript II Reverse Transcriptase (Invitrogen) was used 
under required buffer conditions to generate complementary DNA that 
contained the biotin-labeled oligo-dT on the 3’ end and the barcoded 
oligonucleotide on the 5’ end. Complementary DNA was captured and 
purified using MyOne carboxylate Dynabeads (Life Technologies), then 
PCR amplified using Advantage 2 DNA polymerase (Clontech) using a 
biotinylated oligonucleotide. An aliquot of cDNA was checked for quality 
by agarose gel electrophoresis. Complementary DNA was next captured 
and purified using MyOne C1 streptavidin Dynabeads (Life 
Technologies). The complementary DNA was then processed for Illumina-
based sequencing by fragmentation, end repair, dA tailing, adapter 
ligation, PCR amplification, purification with AMPure XP beads 
(Beckman Coulter), and gel size selection for amplicons 200-400bp in size. 
Samples were then sequencing on HighSeq 2500 (Illumina). Ambion 
ArrayControl RNA spikes (Ambion) were used in each well to assess 
sequencing quality and fidelity. For data analysis, reads were distributed 
into separate samples based on their barcodes. Cells were excluded if 
wells were empty or generated library was low quality as assessed by the 
number of total reads, number of mapped reads, a high percentage of 
unmapped reads and a high percentage of spike-in reads (Stegle et al., 
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2015). To equalize the number of cells analyzed from each population, 
cells were randomly selected and removed from analysis. The RNA-
sequencing pipeline described above was then used to measure gene 
expression across RNA-sequencing data from each cell. In parallel, 
TopHat results were parsed to count the presence of every exon-exon 
junction across all the samples. Transcripts present in both cell 
populations, present in more than 25% of all cells and expressed above 
threshold mean of all cells based on a Gaussian distribution were included 
for analysis. Non-linear cell clustering by t-Distributed Stochastic 
Neighbor Embedding was performed using ‘tsne’ package in R. To 
measure intron retention, the number of reads mapping to each exon or 
intron were counted across the transcriptome for all samples. As a 
measure of intron retention (IR), for each intron, the number of reads 
mapping to that intron relative to the two spanning exons (r_int_ex) was 
calculated. For CV measurements, retained introns and exon-exon 
junctions were included in analysis if present in more than 25% of all cells. 
Pathway analysis 
iPAGE (Goodarzi et al., 2009) pathway analysis 
(http://iget.c2b2.columbia.edu) was used to identify gene sets with 
higher transcript variability in both HV subpopulations. Transcript 
coefficient of variation log-ratios (HV / LV) were used to categorize 
transcripts into four bins: bin 1 = negative log-ratio in both MDA-derived 
and CN-derived comparisons, bins 2&3 = positive log-ratio in either 
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MDA-derived or CN-derived comparison, and bin 4= positive log-ratio in 
both MDA-derived and CN-derived comparisons. GO and KEGG 
annotations were analyzed using a maximum p-value of 0.05 and 
maximum genes per category of 200. Gene sets were only considered 
relevant if enrichment was highest in bin 4 and lowest in bin 1.  
 
Flow cytometry 
For antibody staining, cells were prepared using Cytofix/Cytoperm (BD). 
Dead cells were excluded using Live/DEAD Aqua (Invitrogen). Primary 
antibodies used were anti-XPNPEP3 (Abcam, 1:200), anti-UPF2 (LSBio, 
1:4) anti-ALDOA (Abcam, 1:8), anti-PABP (Abcam; 1:200), anti-HNRNPA1 
(Cell Signaling, 1:30), anti-CD110 (BD, 1:50), anti-HNRNPA0 (Cell 
Signaling, 1:50), anti-ESR1 (Thermo, 1:20), anti-MCF2 (1:10, LSBio, 1:10), 
and anti-CSF2RA (1:30, eBiosciences) conjugated to Alexa555 or Alexa647 
Zenon secondary antibodies (Invitrogen). Data aquisition was performed 
on LSRII (BD). Data analysis was performed on FloJo. CV calculations 
were performed using greater than 25x103 cells, an equal number of cells 
per sample within each experiment. Ratios were calculated using the 
average value of all high variability populations (MDA: HV-M35, HV-
M42, HV-M56; CN: HV-C57) and low variability populations (MDA: LV-
M26, LV-M52, LV-M100; CN: LV-C65, LV-C92, LV-C100). Cell cycle 
analysis was performed by employing flow cytometry on fixed cells 
stained with DAPI and determining cell cycle phases in FloJo. 
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SNRNP40 protein quantitation 
Cells were seeded onto coverslips, fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, and stained with DAPI and anti-
SNRNP40 antibody (HPA026527, 1:100, Sigma) followed by fluorescent-
conjugated secondary antibodies. Imaging was performed on Leica TCS 
SP5 system. SNRNP40 relative protein level was determined using Cell 
Profiler 2.0 by measuring total nuclear SNRNP40 fluorescence intensity as 
demarcated by DAPI signal.  
SNRNP40 cell line generation 
To generate high CV SNRNP40 population, cell populations were 
transduced individually at various titers with either virus for shRNA 
expression (shRNA#1 TRCN0000074608 and shRNA#2 TRCN0000074610, 
Sigma) or virus for stable ORF expression (pBabe puro vector, Addgene 
#1764). Expression in individual populations was confirmed by 
quantitative RT-PCR. Populations were then pooled at equal ratios to 
generate mixed populations. Control population was generated similarly 
using a non-targeting shRNA (SHC016, Sigma) and an empty expression 
vector.  
Quantitative RT-PCR 
RNA was extracted using total RNA isolation kit (Norgen Biotek). cDNA 
was generated using Superscript III (Invitrogen). Fast SYBR Green Master 
Mix (Life Technologies) was used to analyze samples on Applied 
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Biosystems 7900HT. Expression was normalized to GAPDH. Primers 
sequences are as follows: SNRNP40 Forward: 
CAGTGGAGCAGTGATGGAAT; SNRNP40 Reverse: 
CCCTCTCACCTGTTTCACTATC; GAPDH Forward: 
AGCCACATCGCTCAGACAC; GAPDH Reverse: 
GCCCAATACGACCAAATCC; blasticidin Forward: 
CCTGGGATCAAAGCCATAGT; blasticidin Reverse: 
TTAGCCCTCCCACACATAAC; puromycin Forward: 
GTCACCGAGCTGCAAGAA; puromycin Reverse: 
CCGATCTCGGCGAACAC 
 
siRNA transfection 
The following siRNAs were used (IDT): siSNRNP40 #1: 
GGAAUAGACAAUGAUAUC; siSNRNP40 #2: 
GGAUUUGACCGACUGAUA. BLOCK-iT Fluorescent Oligo (Life 
Technologies) and NC1 (IDT) were used as controls.  
105 cells were seeded and were transfected the next day with siRNAs via 
Lipofectaime 2000 (Invitrogen). Cells were extracted 48 hours later for 
validation of knock-down by quantitative RT-PCR or for RNA-
sequencing. For RNA-sequencing, two siRNAs were used for SNRNP40 
and control, and independent siRNA replicates were averaged. 
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Clinical samples 
GSE2034 (Wang et al., 2005) and GSE33926 (Kuo et al., 2012) were used to 
generate Kaplan-Meier curves. Patients were stratified by SNRNP40 
expression relative to median. KMplotter was used to assess distant 
metastasis-free survival with follow up threshold of 8 years (Gyorffy et al., 
2010). TCGA sample data was stratified by SNRNP40 copy number 
relative to median and was used to assess overall survival.(Cancer 
Genome Atlas, 2012) 
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CHAPTER 4: Final Summary 
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The work presented in this thesis addresses two aspects of 
metastatic colonization, the most significant clinical event in advanced 
cancer progression. The first part of this thesis explored the cellular and 
molecular functions of a kinase that promotes liver colonization by 
colorectal cancer, which is a significant cause of cancer mortality. A 
systematic, unbiased approach was utilized to identify genes that promote 
liver colonization in a mouse model of metastasis. PKLR, which encodes 
the liver and red blood cell isozymes of pyruvate kinase, was identified as 
a promoter of colonization of the liver in an organ-specific manner. 
Assessment of PKLR expression in patient samples revealed an 
association of PKLR levels with metastatic disease, consistent with 
functional testing results. Characterization of the cellular defect upon 
PKLR depletion revealed the requirement of PKLR for cell survival in the 
tumor core, a survival defect that can be recapitulated in vitro under 
conditions of high cell density and hypoxia. While PKLR functions under 
physiologic conditions to promote glycolysis in hepatocytes and red blood 
cells, PKLR promotes survival by negatively regulating the glycolytic 
enzymatic activity of the predominant pyruvate kinase expressed in 
cancer, PKM2, and allows for the maintenance of the primary intracellular 
antioxidant, glutathione (Illustration 4.2). Furthermore, inhibition of 
glutathione synthesis by RNAi as well as small-molecule therapy led to a 
suppression of metastatic colonization, indicating the potential for clinical 
utility. Our findings reveal the use of multiple pyruvate kinase isozymes 
by colon cancer for enhanced regulatory control of glycolysis and 
antioxidant generation. Furthermore, the microenvironment conditions 
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that render colon cancer cells susceptible to cell death highlight the 
metabolically demanding conditions upon liver colonization and reveal 
potential for therapeutic targeting of these pathways.  
 
 
Illustration 4.2: Regulation of glycolytic metabolism for metastasis 
 
 
 The second half of this thesis focused on the study of non-genetic 
diversity as a contributor to metastatic fitness. First, imaging analysis of 
clonal subpopulations derived from human breast cancer cells lines was 
performed to enable the identification of subpopulations that generate 
phenotypic variability. Characterization of these high variability 
subpopulations revealed that phenotypic variability was heritable in 
progeny and was relevant in multiple phenotypes.  Consistent with a 
positive role of diversification in cancer progression, high variability 
subpopulations displayed increased metastatic fitness. Variability did not 
appear to be genetic in nature as subpopulation genomic integrity 
appeared intact. However, single cell transcriptomic analyses reveal 
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elevated cell-to-cell gene expression variability that was maintained 
within clonal cancer subpopulations. Furthermore, spliceosome-associated 
gene expression variability was identified as one potential mechanism by 
which clonal cancer populations could increase mature transcript 
expression variability of target genes. One example of a functional role for 
spliceosome gene expression variability was explored where engineered 
variable cell-to-cell expression of SNRNP40 enabled enhanced metastatic 
fitness through existence of a subpopulation with low SNRNP40 
expression (Illustration 4.3). Importantly, gene expression profiles upon 
SNRNP40 deregulation was consistent with this gene’s contribution to 
gene expression variability observed in high variability subpopulations. 
The consistent molecular variability observed in high variability 
subpopulations derived from independent human cancer cell populations 
was measured under different experimental assays and at both the 
molecular and phenotypic levels, suggesting that the variability is 
molecularly conserved and deterministic in nature. These experimental 
observations can be tested in clinical correlates to characterize non-genetic 
contributions to tumor evolution in patients. 
Illustration 4.1: Model of spliceosome expression variability mediating 
gene expression changes and metastatic capacity. 
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